Document:

Exhibit 10.2

 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON
EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR ANY STATE SECURITIES LAW, AND MAY NOT BE OFFERED FOR SALE, SOLD OR TRANSFERRED UNLESS A REGISTRATION STATEMENT UNDER SUCH ACT
AND APPLICABLE STATE SECURITIES LAWS SHALL BE EFFECTIVE WITH RESPECT THERETO, OR AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT AND APPLICABLE STATE SECURITIES LAWS IS AVAILABLE IN CONNECTION WITH SUCH OFFER, SALE OR TRANSFER.

 

Champions Oncology, Inc.

 

WARRANT

 

	Warrant No. [•]	 	Dated: March 13, 2015

 

Champions Oncology, Inc., a Delaware corporation
(the “Company”), hereby certifies that, for value received, [Name_of_Investor] or its registered assigns (the
“Holder”), is entitled to purchase from the Company up to a total of [•] fully paid and non-assessable
shares of common stock, $0.001 par value per share (the “Common Stock”), of the Company (each such share, a
“Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price equal to
$0.48 per share (subject to appropriate adjustment provided in Section 9 herein, the “Exercise Price”), at any
time after the date hereof (the “Initial Exercise Date”) and through and including the date that is sixty (60)
months from the date hereof (or, if such date is not a Business Day, on the Business Day immediately following such date) (the
“Expiration Date”), subject to the following terms and conditions. This Warrant (this “Warrant”)
is one of a series of similar warrants issued pursuant to that certain Securities Purchase Agreement, dated as of March 11, 2015,
by and among the Company and the Investors identified therein (the “Purchase Agreement”). All such warrants
are referred to herein, collectively, as the “Warrants.”

 

1. Definitions. In addition to the terms
defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings given to such terms
in the Purchase Agreement.

 

2. Registration of Warrant. The Company
shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of record of this
Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.

 

3. Transfers and Registration of Transfers.
The Holder may sell, transfer, assign, pledge or otherwise dispose of this Warrant, in whole or in part, as long as such sale or
other disposition is made pursuant to an effective registration statement or an exemption from the registration requirements of
the Securities Act, in which case the Holder shall provide an opinion of counsel reasonably acceptable to the Company that such
transfer or other disposition is so exempt. Upon such transfer or other disposition (other than a pledge), the Holder shall deliver
this Warrant to the Company together with a written notice to the Company, substantially in the form of the Transfer Notice attached
hereto as Exhibit A (the “Transfer Notice”), indicating the person or persons to whom this Warrant shall be
transferred and, if less than all of this Warrant is transferred, the number of Warrant Shares to be covered by the part of this
Warrant to be transferred to each such person. The Company shall register the transfer of any portion of this Warrant in the Warrant
Register, upon surrender of this Warrant, with the Transfer Notice duly completed and signed, to the Company at its address specified
in the Purchase Agreement. Within three (3) Business Days of any such registration of transfer, a new warrant to purchase Common
Stock, in substantially the form of this Warrant (any such new warrant, a “New Warrant”), evidencing the portion
of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant
not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof
shall be deemed the acceptance by such transferee of all of the rights and obligations of a holder of a Warrant.

 

    	 

    	 

    

 

4. Exercise and Duration of Warrants.

 

(a) This Warrant shall be exercisable by the
registered Holder at any time and from time to time on or after the Initial Exercise Date and including the Expiration Date, as
to all or any part of the Warrant Shares covered hereby. At 6:00 p.m., New York City time on the Expiration Date, the portion of
this Warrant not exercised prior thereto shall be and become void and of no value.

 

(b) A Holder may exercise this Warrant by
delivering to the Company (i) an exercise notice, in the form attached hereto (the “Exercise Notice”),
appropriately completed and duly signed, and (ii) either (A) in the case of a cash exercise in immediately available funds
(“Cash Exercise”), payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is
being exercised, or (B) in the event of a Cashless Exercise (as defined below), no payment is required; and the date such items
are delivered to the Company (as determined in accordance with the notice provisions hereof) is an “Exercise Date.”
The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery
of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing
the right to purchase the remaining number of Warrant Shares.

 

(c) In the case of a dispute between the Company
and the Holder as to the calculation of the Exercise Price or the number of Warrant Shares issuable hereunder (including, without
limitation, the calculation of any adjustment pursuant to Section 9 below), the Company shall issue to the Holder the number of
Warrant Shares that are not disputed within the time periods specified in Section 5 below and shall submit the disputed calculations
to a certified public accounting firm of national recognition (other than the Company’s regularly retained accountants) within
three (3) Business Days following the Company’s receipt of the Holder’s Exercise Notice. The Company shall cause such
accountant to calculate the Exercise Price and/or the number of Warrant Shares issuable hereunder and to notify the Company and
the Holder of the results in writing no later than three (3) Business Days following the day on which such accountant received
the disputed calculations (the “Dispute Procedure”). Such accountant’s calculation shall be deemed conclusive
absent manifest error. The fees of any such accountant shall be borne by the party whose calculations were most at variance with
those of such accountant.

 

    	2

    	 

    

 

5. Delivery of Warrant Shares.

 

(a) Upon exercise of this Warrant, the Company
shall, (A) in the case of a Cash Exercise, no later than the close of business on the later to occur of (i) the third (3rd) Business
Day following the Exercise Date set forth in such Exercise Notice and (ii) such later date on which the Company shall have received
payment of the Exercise Price, (B) in the case of a Cashless Exercise, no later than the close of business on the third (3rd) Business
Day following the Exercise Date set forth in such Exercise Notice, and (C) with respect to Warrant Shares that are the subject
of a Dispute Procedure, the close of business on the third (3rd) Business Day following the determination made pursuant to Section
4(c) (each of the dates specified in (A), (B) or (C) being referred to as a “Delivery Date”), the Company shall
promptly issue or cause to be issued and cause to be delivered to or upon the written order of the Holder and in such name or names
as the Holder may designate, a certificate for the Warrant Shares issuable upon such exercise, free of restrictive legends unless
a legend is required to be placed on the certificate pursuant to Section 2.1(f) of the Purchase Agreement. The Holder, or
any Person so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant
Shares as of the Exercise Date. The Company shall, provided that the Transfer Agent is participating in The Depository Trust Company
(“DTC”) Fast Automated Securities Transfer Program (“FAST”), use its commercially reasonable
efforts to credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder’s
or its designee’s balance account with DTC through its Deposit Withdrawal Agent Commission system (“DWAC”);
provided further, that the Holder provides the Company the reasonably necessary details to effect the foregoing DWAC delivery.
In the event that the Transfer Agent is not a participant in FAST, or if the Warrant Shares are not otherwise eligible for delivery
through FAST, or if the Holder so specifies in an Exercise Notice or otherwise in writing on or before the Exercise Date, the Company
shall effect delivery of Warrant Shares by delivering to the Holder or its nominee physical certificates representing such Warrant
Shares, no later than the close of business on such Delivery Date. Warrant Shares delivered to the Holder shall not contain any
restrictive legend as long as such Warrant Shares have been resold (as certified in writing by the Holder to the Company (x) pursuant
to an effective Registration Statement (as defined in the 2015 Amended and Restated Registration Rights Agreement) or (y) pursuant
to Rule 144 under the Securities Act.

 

(b) This Warrant is exercisable, either in
its entirety or, from time to time, for a portion of the number of Warrant Shares. Upon surrender of this Warrant following one
or more partial exercises, the Company shall issue or cause to be issued, at its expense, a New Warrant evidencing the right to
purchase the remaining number of Warrant Shares; provided, however, that the Holder shall be entitled to exercise all or
any portion of such New Warrant at any time following the time at which this Warrant is exercised, regardless of whether the Company
has actually issued such New Warrant or delivered to the Holder a certificate therefor.

 

(c) The Company’s obligations to issue
and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction
by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against
any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach
or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law
by the Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the
Company to the Holder in connection with the issuance of Warrant Shares.

 

(d) In the event that the Company fails for
any reason to deliver to the Holder the number of Warrant Shares specified in the applicable Exercise Notice on or before the Delivery
Date therefor (an “Exercise Default”), the Company shall pay to the Holder payments (“Exercise Default
Payments”) in the amount of (i) (N/365) multiplied by (ii) the aggregate Exercise Price of the Warrant Shares
which are the subject of such Exercise Default multiplied by (iii) the lower of twelve percent (12%) per annum and the maximum
rate permitted by applicable law (the “Default Interest Rate”), where “N” equals the number of days
elapsed between the original Delivery Date of such Warrant Shares and the date on which all of such Warrant Shares are issued and
delivered to the Holder. Cash amounts payable hereunder shall be paid on or before the fifth (5th) Business Day of each calendar
month following the calendar month in which such amount has accrued.

 

    	3

    	 

    

 

(e) In the event of an Exercise Default, the
Holder may, upon written notice to the Company, regain on the date of such notice the rights of the Holder under the exercised
portion of this Warrant that is the subject of such Exercise Default. In such event, the Holder shall retain all of the Holder’s
rights and remedies with respect to the Company’s failure to deliver such Warrant Shares (including without limitation the
right to receive the cash payments specified in Section 5(d) above); provided, however, that such cash payments shall cease
to accrue effective as of the date of such notice.

 

(f) The Holder’s rights and remedies
hereunder are cumulative, and no right or remedy is exclusive of any other. In addition to the amounts specified herein, the Holder
shall have the right to pursue all other remedies available to it at law or in equity (including, without limitation, a decree
of specific performance and/or injunctive relief). Nothing herein shall limit the Holder’s right to pursue actual damages
for the Company’s failure to issue and deliver Warrant Shares on the applicable Delivery Date (including, without limitation,
damages relating to any purchase of Common Stock by the Holder to make delivery on a sale effected in anticipation of receiving
Warrant Shares upon exercise, such damages to be in an amount equal to (A) the aggregate amount paid by the Holder for the Common
Stock so purchased minus (B) the aggregate amount of net proceeds, if any, received by the Holder from the sale of
the Warrant Shares issued by the Company pursuant to such exercise).

 

6. Charges, Taxes and Expenses. Issuance
and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder
for any issue or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense in respect of the issuance
of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not
be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for
Warrant Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability
that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

 

7. Replacement of Warrant. If this Warrant
is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon
cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably
satisfactory to the Company of such loss, theft or destruction and customary and reasonable bond or indemnity, if requested. Applicants
for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such
other reasonable third-party costs as the Company may prescribe.

 

8. Reservation of Warrant Shares. The
Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and
otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant
as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the exercise of this entire Warrant,
free from preemptive rights or any other contingent purchase rights of persons other than the Holder (after giving effect to the
adjustments and restrictions of Section 9, if any). The Company covenants that all Warrant Shares so issuable and deliverable
shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly
authorized, issued and fully paid and nonassessable. The Company will take all such action as may be necessary to assure that such
shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of any securities exchange or automated quotation system upon which the Common Stock may be listed.

 

9. Certain Adjustments. The Exercise
Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth
in this Section 9.

 

    	4

    	 

    

 

(a) Stock Dividends and Splits. If
the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions
on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for
avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides
outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding
shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares
of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator
shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and
of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number
of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 9(a) shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision, combination or re-classification.

 

(b) Pro Rata Distributions. If the
Company, at any time while this Warrant is outstanding, distributes to holders of Common Stock (i) evidences of its indebtedness,
(ii) any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights or warrants
to subscribe for or purchase any security, or (iv) cash or any other asset, or rights to acquire such assets, as a partial
liquidating dividend or otherwise, including without limitation any dividend or distribution to the Company’s stockholders
in shares (or rights to acquire shares) of capital stock of a subsidiary (in each case, “Distributed Property”),
then in each such case the Holder shall be entitled, upon exercise of this Warrant for the purchase of any or all of the Warrant
Shares, to receive the amount of Distributed Property which would have been payable to the Holder had such Holder been the holder
of such Warrant Shares on the record date for the determination of stockholders entitled to such Distributed Property. The Company
will at all times set aside in escrow and keep available for distribution to such holder upon exercise of this Warrant a portion
of the Distributed Property to satisfy the distribution to which such Holder is entitled pursuant to the preceding sentence. The
Company shall deliver written notice of such distribution of Distributed Property (a “Distribution Notice”)
to the Holder at least thirty (30) days prior to the earlier to occur of (i) the record date for determining stockholders
entitled to such Distribution and (ii) the date on which such distribution is made (the “Distribution Date”).
In the Distribution Notice to a Holder, the Company must indicate whether the Company has elected (A) to deliver to such Holder
the same amount and type of Distributed Property as though the Holder were a holder on the determination date therefor of a number
of shares of Common Stock into which the this Warrant is exercisable as of such determination date (such number of shares to be
determined at the Exercise Price then in effect and without giving effect to any limitations on such exercise) or (B) to reduce
the Exercise Price as of the determination date therefor by an amount equal to the fair market value of the Distributed Property
divided by the number of shares of Common Stock as to which such distribution is to be made, such fair market value to be
reasonably determined in good faith by the independent members of the Company’s Board of Directors. If the Company does not
notify the Holders of its election pursuant to the preceding sentence within two (2) Business Days following the date on which
the Company publicly announces a distribution, the Company shall be deemed to have elected clause (A) of the preceding sentence.

 

    	5

    	 

    

 

(c)Fundamental Transactions. If,
at any time while this Warrant is outstanding, (i) the Company effects any merger or consolidation of the Company with or
into another Person, (ii) the Company effects any sale of all or substantially all of its assets in one or a series of related
transactions, (iii) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to
which holders of Common Stock owning more than 50% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the Person or Persons making or affiliated with the Persons making the tender or exchange offer) tender or exchange
their shares for other securities, cash or property, or (iv) the Company effects any reclassification of the Common Stock
or any compulsory share exchange or any other transaction pursuant to which the Common Stock is effectively converted into or exchanged
for other securities, cash or property of the Company or another entity (other than as a result of a subdivision or combination
of shares of Common Stock covered by Section 9(a) above) (in any such case, a “Fundamental Transaction”),
then the Holder shall have the right thereafter to receive, upon exercise of this Warrant, on a per share basis, the same amount
and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction
if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon
exercise of this Warrant (the “Alternate Consideration”). The aggregate Exercise Price for this Warrant will
not be affected by any such Fundamental Transaction, but the Company shall apportion such aggregate Exercise Price among the Alternate
Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction,
then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. At the Holder’s request, any successor to the Company or surviving entity in such
Fundamental Transaction shall issue to the Holder a New Warrant consistent with the foregoing provisions and evidencing the Holder’s
right to purchase the Alternate Consideration for the aggregate Exercise Price upon exercise thereof. The terms of any agreement
pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to
comply with the provisions of this paragraph (c) and insuring that the Warrant (or any such replacement security) will be
similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction.

 

(e) Number of Warrant Shares. Simultaneously
with any adjustment to the Exercise Price pursuant to Section 9(a), the number of Warrant Shares that may be purchased upon
exercise of this Warrant shall be adjusted proportionately, so that after such adjustment the aggregate Exercise Price payable
hereunder for the increased or decreased number of Warrant Shares, as applicable, shall be the same as the aggregate Exercise Price
in effect immediately prior to such adjustment. In the event that at any time, as a result of an adjustment made pursuant to this
Section 9, the Holder of this Warrant shall, upon exercise of this Warrant, become entitled to receive securities or assets (other
than Common Stock) then, wherever appropriate, all references herein to shares of Common Stock shall be deemed to refer to and
include such shares and/or other securities or assets; and thereafter the number of such shares and/or other securities or assets
shall be subject to adjustment from time to time in a manner and upon terms as nearly equivalent as practicable to the provisions
of this Section 9. Any adjustment made herein pursuant to Section 9(a) that results in a decrease in the Exercise Price shall also
effect a proportional increase in the number of shares of Common Stock into which this Warrant is exercisable.

 

(f) Calculations. The number of shares
of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Company, and
the disposition of any such shares shall be considered an issue or sale of Common Stock.

 

    	6

    	 

    

 

(g) Notice of Adjustments. Upon the
occurrence of each adjustment pursuant to this Section 9 or any change in the number or type of stock, securities and/or other
property issuable upon exercise of this Warrant, the Company at its expense will promptly compute such adjustment or change in
accordance with the terms of this Warrant and prepare a certificate (an “Adjustment Notice”) setting forth such
adjustment or change, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other
securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments
or changes and showing in detail the facts upon which such adjustment or change is based and, on or before the time that it delivers
an Adjustment Notice, publicly disclose the contents thereof. Upon written request, the Company will promptly deliver a copy of
each such Adjustment Notice to the Holder and to the Transfer Agent. The failure of the Company to deliver an Adjustment Notice
shall not affect the validity of any such adjustment.

 

(h) Notice of Corporate Events. If
the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common
Stock, including without limitation any granting of rights or warrants to subscribe for or purchase any capital stock of the Company
or any Subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for
any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the
Company, then the Company shall deliver to the Holder a notice describing the material terms and conditions of such transaction,
at least ten (10) Business Days prior to the applicable record or effective date on which a Person would need to hold Common
Stock in order to participate in or vote with respect to such transaction (or if no such date is applicable, at least ten (10)
Business Days prior to the closing or effectiveness of the transaction), and the Company will take all steps reasonably necessary
in order to insure that the Holder is given the practical opportunity to exercise this Warrant prior to such time so as to participate
in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect
therein shall not affect the validity of the corporate action required to be described in such notice. The notice requirements
in this Section 9(h) shall be in addition to the requirements for notice in connection with Distributed Property as set forth in
Section 9(b) hereof.

 

10. Payment of Exercise Price. The Holder
shall pay the Exercise Price (i) through a Cash Exercise or (ii) if an effective Registration Statement is not available
for the resale of all of the Warrant Shares issuable hereunder at the time an exercise notice, in the form attached hereto as Exhibit
B (the “Exercise Notice”), is delivered to the Company, through a “cashless exercise” (a “Cashless
Exercise”) in which event the Company shall issue to the Holder the number of Warrant Shares determined as follows:

 

	 	 	 
	 	 	X = Y * [(A-B)/A]
	 	 
	where:	 	 
	 	 
	 	 	X = the number of Warrant Shares to be issued to the Holder.
	 	 
	 	 	Y = the number of Warrant Shares with respect to which this Warrant is being exercised.
	 	 
	 	 	A = the Market Price (as defined below) as of the Exercise Date.
	 	 
	 	 	B = the Exercise Price.

 

    	7

    	 

    

 

For purposes of Rule 144 promulgated under the Securities Act, it
is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction shall be deemed to have
been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this
Warrant was originally issued pursuant to the Purchase Agreement. “Market Price” shall mean for any date, the
price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a stock
exchange, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the stock
exchange on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)  the volume weighted average price of the Common Stock for such
date (or the nearest preceding date) on the OTC Bulletin Board, (c) if the Common Stock is not then listed or quoted for trading
on the OTC Bulletin Board and if prices for the Common Stock are then reported in the “Pink Sheets” published by Pink
OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price
per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as
determined by an independent appraiser selected in good faith by the Investors of a majority in interest of the Shares then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

11. Fractional Shares. The Company shall
not be required to issue or cause to be issued fractional Warrant Shares on the exercise of this Warrant. If any fraction of a
Warrant Share would, except for the provisions of this Section 11, be issuable upon exercise of this Warrant, the Company shall,
in lieu of issuing any such fractional share, pay to the Holder an amount in cash equal to the product resulting from multiplying
such fraction by the Market Price as of the Exercise Date.

 

12. Notices. Any and all notices or
other communications or deliveries hereunder (including without limitation any Exercise Notice) shall be in writing and shall be
deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via
facsimile at the facsimile number specified in the Purchase Agreement prior to 6:30 p.m. (New York City time) on a Trading Day,
(ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the
facsimile number specified in the Purchase Agreement on a day that is not a Trading Day or later than 6:30 p.m. (New York City
time) on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight
courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. The address for such
notices or communications shall be as set forth in the Purchase Agreement with respect to the Company and, with respect to the
Holder, the Holder’s last address as shown on the Warrant Register.

 

13. Warrant Agent. The Company shall
serve as warrant agent under this Warrant. Upon thirty (30) days’ notice to the Holder, the Company may appoint a new
warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from
any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any
new warrant agent transfers substantially all of its corporate trust or stockholder services business shall be a successor warrant
agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession
as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown
on the Warrant Register.

 

    	8

    	 

    

 

14. Limitation on Exercise.  

 

[(a) The Company shall not effect the exercise
of this Warrant, and the Holder shall not have the right to exercise this Warrant, to the extent that after giving effect to such
exercise, such Person (together with such Person's affiliates) would beneficially own in excess of 9.99% (the "Maximum
Percentage") of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes
of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Person and its affiliates
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination
of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (i) exercise of the remaining,
unexercised portion of this Warrant beneficially owned by such Person and its affiliates and (ii) exercise or conversion of the
unexercised or unconverted portion of any other securities of the Company beneficially owned by such Person and its affiliates
(including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion
or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph,
beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. For purposes of this Warrant, in
determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common
Stock as reflected in (1) the Company's most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with
the Securities and Exchange Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any other
notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. For any reason at any
time, upon the written or oral request of the Holder, the Company shall within two (2) Business Days confirm orally and in writing
to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock
shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by
the Holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. By written
notice to the Company, the Holder may waive the provisions of this Section 14 or increase or decrease the Maximum Percentage to
any other percentage specified in such notice, but (i) any such waiver or increase will not be effective until the sixty-first
(61st) day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the
Holder and not to any other holder of Warrants.

 

(b) The Company’s obligation to issue
shares of Common Stock in excess of any limitation referred to in this Section 14 shall be suspended (and shall not terminate or
expire notwithstanding any contrary provisions hereof) until such time, if any, as such shares of Common Stock may be issued in
compliance with such limitation, but in no event later than the Expiration Date.

 

(c) The provisions of this Section 14 shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 14 to correct this
Section 14 (or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.]1

 

15. Miscellaneous.

 

(a) Subject to the restrictions on transfer
set forth on the first page hereof, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company
except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on the parties hereto and their
respective successors and assigns. This Warrant shall be for the sole and exclusive benefit of the Holder of this Warrant and nothing
in this Warrant shall be construed to confer upon any person other than the Holder of this Warrant any legal or equitable right,
remedy or claim hereunder.

 

 

1
ONLY WITH RESPECT TO NEA.

 

    	9

    	 

    

 

(b) The Company will not, by amendment of
its governing documents or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of
securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be
necessary or appropriate in order to protect the rights of the Holder against impairment. Without limiting the generality of the
foregoing, the Company (i) will not increase the par value of any Warrant Shares above the amount payable therefor on such
exercise, (ii) will take all such action as may be reasonably necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable Warrant Shares on the exercise of this Warrant, and (iii) will not close its
stockholder books or records in any manner which interferes with the timely exercise of this Warrant.

 

(c) Nothing contained in this Warrant shall
be construed as imposing any liabilities on the Holder as a stockholder of the Company, whether such liabilities are asserted by
the Company or by creditors of the Company. Until the exercise of this Warrant, the Holder shall not have nor exercise any rights
by virtue hereof as a stockholder of the Company. Notwithstanding the foregoing, in the event (a) the Company effects a split
of the Common Stock by means of a stock dividend and the Exercise Price of and the number of Shares are adjusted as of the date
of the distribution of the dividend (rather than as of the record date for such dividend), and (b) the Holder exercises this
Warrant between the record date and the distribution date for such stock dividend, the Holder shall be entitled to receive, on
the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such exercise, notwithstanding
the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend.

 

(d) All questions concerning the construction,
validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the
laws of the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the city of New York, borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the transaction
documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not
personally subject to the jurisdiction of any such court, or that such suit, action or proceeding is improper. Each party hereby
irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under Section 12 hereof and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner
permitted by law. The Company hereby waives all rights to a trial by jury.

 

(e) The headings herein are for convenience
only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.

 

(f) In case any one or more of the provisions
of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions
of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a
valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate
such substitute provision in this Warrant.

 

(g)No amendment, modification or other
change to, or waiver of any provision of, this Warrant may be made unless such amendment, modification or change is (i) set forth
in writing and is signed by the Company and (ii) agreed to in writing by the holders of Warrants exercisable for a majority of
the number of shares into which the all of the then outstanding Warrants issued pursuant to the Purchase Agreement are exercisable
(without regard to any limitation contained herein on such exercise), it being understood that upon the satisfaction of the conditions
described in (i) and (ii) above, each Warrant (including any Warrant held by the Holder who did not execute the agreement specified
in (ii) above) shall be deemed to incorporate any amendment, modification, change or waiver effected thereby as of the effective
date thereof.

 

SIGNATURE PAGE FOLLOWS

 

    	10

    	 

    

 

IN WITNESS WHEREOF, the Company has caused
this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

 

	 	 	 	 
	 	CHAMPIONS ONCOLOGY, INC.
	 	 	 
	 	By:	 	
        /s/ Joel Ackerman 

	 	Name:	 	
         Joel
        Ackerman

	 	Title:	 	
         Chief
        Executive Officer

 

    	11

    	 

    

 

EXHIBIT A

 

TRANSFER NOTICE

 

[To be completed and signed only upon transfer
of Warrant]

 

FOR VALUE RECEIVED, the undersigned hereby
sells, assigns and transfers unto                     
the right represented by the within Warrant to purchase                     
shares of Common Stock of Champions Oncology, Inc. to which the within Warrant relates and appoints                     
attorney to transfer said right on the books of Champions Oncology, Inc. with full power of substitution in the premises.

 

	Dated:                     ,         	 	 
	 	 	 
	 	 	(Signature must conform in all respects to name of holder as specified on the face of the Warrant)
	 	 	 
	 	 	 
	 	 	 
	 	 	Address of Transferee
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	Taxpayer Identification Number

 

 

    	 

    	 

    

 

EXHIBIT B 

 

(To be executed by the Holder to exercise the
right to purchase shares of

 

Common Stock under the foregoing Warrant)

 

To Champions Oncology, Inc.:

 

The undersigned is the Holder of Warrant No.             
(the “Warrant”) issued by Champions Oncology, Inc., a Delaware corporation (the “Company”).
[The undersigned Holder acknowledges that the sale, transfer, assignment or hypothecation of the Warrant Shares to be issued upon
exercise of this Warrant is subject to the terms and conditions contained in Section 14 of this Warrant.]2
Capitalized terms used herein and not otherwise defined have the respective meanings set forth in the Warrant.

 

	1.	The Warrant is currently exercisable to purchase a total of                      Warrant Shares.

 

	2.	The undersigned Holder hereby exercises its right to purchase                      Warrant Shares pursuant to the Warrant.

 

	3.	The Holder intends that payment of the Exercise Price shall be made as (check one):

 

            
“Cash Exercise” under Section 10      

 

            
“Cashless Exercise” under Section 10

 

	4.	If the holder has elected a Cash Exercise, the holder shall pay the sum of $         to the Company in accordance with the terms of the Warrant.

 

	5.	Pursuant to this exercise, the Company shall deliver to the holder                      Warrant Shares in accordance with the terms of the Warrant.

 

	6.	Following this exercise, the Warrant shall be exercisable to purchase a total of                      Warrant Shares.

 

 

2 Include in NEA warrant only.

 

    	 

    	 

    

 

	Dated:                      ,             	 	Name of Holder:
	 	 	(Print)  	 
	 	 	By:  	 
	 	 	Name:  	 
	 	 	Title:  	 

 

	 	 	(Signature must conform in all respects to name of holder as specified on the face of the Warrant)
	 	 	 
	 	 	Taxpayer Identification Number
	 	 	 
	
        ACKNOWLEDGED AND AGREED TO this      day
        of             , 20     
	 	 
	 	 	 
	CHAMPIONS ONCOLOGY, INC.	 	 
	 	 	 
	By:  	 	 	 
	Name:  	 	 	 
	Title:Exhibit 10.3

 

AMENDED AND
RESTATED 2011 SECURITIES PURCHASE AGREEMENT

 

This AMENDED AND RESTATED
2011 SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March 13, 2015, by and between Champions
Oncology, Inc. (the “Company”) (previously known as Champions Biotechnology, Inc.), Battery Ventures IX, L.P.
(“Ventures”), Battery Investment Partners IX, LLC (together with Ventures, “Battery”), Joel
Ackerman (“Ackerman”) and Ronnie Morris (“Morris”) amends and restates in its entirety the
Securities Purchase Agreement dated as of March 24, 2011 (the “Original 2011 Securities Purchase Agreement”)
between the Company, Battery, Ackerman, Morris and the other parties to the Original 2011 Securities Purchase Agreement (such parties,
Battery, Ackerman and Morris being the “Investors”), as amended by the Amendment No. 1 to 2011 Securities Purchase
Agreement dated January 29, 2014.

 

A.         Pursuant
to the Original 2011 Securities Purchase Agreement, the Company sold to each Investor, and each Investor purchased, on the terms
and subject to the conditions set forth in the Original 2011 Securities Purchase Agreement, (i) shares (the “Shares”)
of the Company’s common stock, $.001 par value per share (the “Common Stock”), and (ii) a Warrant in the
form attached thereto as Exhibit A (each, a “Warrant” and, collectively with the other Warrants issued
thereunder, the “Warrants”). The shares of Common Stock into which the Warrants are exercisable are referred
to herein as the “Warrant Shares”, and the Shares, the Warrants, the Warrant Shares and the Put Option Shares
(as defined below) are collectively referred to herein as the “Securities”.

 

B.         Battery,
Ackerman and Morris constitute the holders of at least a majority of the number of Shares and Warrant Shares into which all of
the Warrants then outstanding are exercisable, and thus this Agreement is binding upon all of the parties, including all of the
Investors, to the Original 2011 Securities Purchase Agreement pursuant to Section 7.12 of the Original 2011 Securities Purchase
Agreement.

 

C.         The
Company, Battery, Ackerman and Morris wish to amend and restate the Original 2011 Securities Purchase Agreement, including to add
a limitation with respect to the Put Right (as defined herein) and to delete the provisions of the Original 2011 Securities Purchase
Agreement regarding the issuance of anti-dilution shares for financings executed after the date of this Agreement.

 

In consideration of the mutual
promises made herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the Company and each Investor hereby agree as follows:

 

    	1

    	 

    

 

1.           Purchase
and Sale of Shares and Warrants and Put Shares.

 

1.1.         Closing
of Purchase and Sale; Purchase Price. Upon the terms and subject to the satisfaction or waiver of the conditions set forth
in the Original 2011 Securities Purchase Agreement, the Company agreed to sell and each Investor agreed to purchase (i) the number
of Shares set forth below such Investor’s name on the signature pages thereof, and (ii) a Warrant, if such Investor received
a Warrant, as indicated below such Investor’s name on the signature page thereof. The date on which the initial closing of
a purchase and sale pursuant to the terms of the Original 2011 Securities Purchase Agreement occurred (the “Initial Closing”)
is hereinafter referred to as the “Initial Closing Date”. The Initial Closing was deemed to occur at the offices
of Neuberger, Quinn, Gielen, Rubin & Gibber, P.A., One South Street, 27th Floor, Baltimore, Maryland 21202, when
(A) the Original 2011 Securities Purchase Agreement and the other Transaction Documents (as defined below) were executed and delivered
by the Company and, to the extent applicable, by each Investor, (B) each of the conditions to the Closing described in Section
6 hereof was satisfied or waived as specified therein and (C) full payment of each Investor’s Purchase Price (as defined
below) was made by such Investor to the Company by wire transfer of immediately available funds against physical delivery by the
Company of duly executed certificates representing the Shares and Warrant being purchased by such Investor. If, subsequent to the
Initial Closing Date, additional Investors purchase Shares pursuant to the terms of this Agreement, the closings of such additional
purchases shall hereinafter be referred to as “Additional Closings” and the date on which each such Additional
Closing takes place is hereinafter referred to as “Additional Closing Dates”.

 

1.2.         Exercise
of Investor Put Option.

 

(a)          Subject
to adjustments pursuant to Section 1.2(b), if any, upon the occurrence of a Put Option Trigger Event, each Investor shall have
the right to elect to require the Company to acquire, severally and not jointly, from such Investor the Shares held by such Investor
(the “Put Shares”) for an amount equal to the number of Put Shares times the Per Share Price (the “Put
Right”). An Investor may exercise their Put Right by delivering written notice to the Company (the “Put Option
Exercise Notice”) within thirty (30) days of a Put Option Trigger Event (the “Put Option Exercise Deadline”),
which shall indicate (x) the total number of Put Shares to be acquired from the exercising Investor and (y) the Business Day on
which the closing of the purchase of the Put Shares subject to the Put Option Exercise Notice shall occur (the “Put Option
Closing”); provided, however, that the Put Option Closing shall occur at least five (5) Business Days following the Put
Option Exercise Deadline and no later than ninety (90) Business Days following the Put Option Exercise Deadline.

 

(b)          Adjusted
Put Shares. In the event that the Company does not have sufficient Legally Available Cash (as defined below) to satisfy all
of its put right obligations in this Agreement and the Other Securities Purchase Agreements, the Put Right for an Investor shall
be limited to a number of Put Shares (“Adjusted Put Shares”) equal to the following (rounded to the nearest
whole number):

 

APS = [(X * [(A*Y)/((A*Y)+(B*Z)+(C*W))]]
/ Y

 

APS = Adjusted Put Shares

 

X = Legally Available Cash

 

A = total number of Put Shares that an Investor elects to
have repurchased pursuant to such Investor’s Put Right in connection with the relevant Put Option Triggering Event

 

B = total number of put shares that 2013 Investors elect
to have repurchased pursuant to such investors’ put rights in the Amended and Restated 2013 Purchase Agreement in connection
with the relevant Put Option Triggering Event

 

    	2

    	 

    

 

C = total number of put shares that 2015 Investors elect
to have repurchased pursuant to such investors’ put rights in the 2015 Purchase Agreement in connection with the relevant
Put Option Triggering Event

 

Y = Per Share Price

 

Z = Per Share Price (as defined in the Amended and Restated
2013 Purchase Agreement)

 

W = Per Share Price (as defined in the 2015 Purchase Agreement)

 

“Legally Available Cash”
means the maximum of amount of cash that the Company is legally permitted (as determined by an opinion of counsel) to spend on
the repurchase of shares of Common Stock from the Investors, the 2013 Investors and/or the 2015 Investors, whether or not such
maximum amount of cash is then actually available to the Company.  If there are no legal restrictions on the repurchase of
Common Stock held by the Investors, the 2013 Investors and/or the 2015 Investors, then “Legally Available Cash” shall
be deemed to be in excess of the amount necessary to satisfy all of the Company’s put right obligations under this Agreement
and the Other Securities Purchase Agreements, and as such this clause (b) shall not apply.

 

(a)          The
Put Right shall terminate for all Investors if one of the following events (each a “Put Option Termination Event”)
has occurred:

 

(i)          the
daily VWAP of the Common Stock is greater than or equal to two hundred and fifty percent (250%) of the Per Share Price for any
consecutive forty trading-day period (the “Measurement Period”) and (y) the daily volume traded in Common Stock
has averaged at least 250,000 shares during such Measurement Period, provided that such daily volume shall be adjusted proportionately
to account for any stock splits or reverse stock splits of the Common Stock;

 

(ii)         (x)
the Company completes a public offering of its Common Stock with gross proceeds of at least fifteen million dollars ($15,000,000)
at a price per share that equals or exceeds two hundred and fifty percent (250%) of the Per Share Price and (y) the Shares held
by the Investors at such time are registered on an effective registration statement;

 

(iii)        a
sale by one of the Investors of twenty-five percent (25%) of the Share held by such investor, provided, however, that a
sale by such Investor will only affect such Investor and will not affect the Put Right of any other Investor; or

 

(iv)        both
Battery (or, if the Put Option has terminated as to Battery but not as to HHG, HHG) and the Company consent in writing to terminate
the Put Right as set forth in this Section 1.02.

 

(c)          Put
Option Closing. Upon the terms and subject to the satisfaction or waiver of the conditions set forth herein, the Company shall
purchase from each Investor delivering a Put Option Exercise Notice, severally, but not jointly, at the Put Option Closing, the
number of Put Shares to be purchased from such Investor in accordance with Section 1.2(a). Each Put Option Closing shall occur
at 10:00 a.m., New York City time, on the date specified in the Put Option Exercise Notice (or such later date as is mutually agreed
to by the Company and each Investor) after notification of satisfaction (or waiver) of the conditions to such Closing set forth
in Section 6 below at the offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP, 850 Winter Street, Waltham,
MA 02451 or such other place as the Company and the affected Investor may agree. The date on which any such Closing occurs is hereinafter
referred to herein as the “Put Option Closing Date.”

 

    	3

    	 

    

 

1.3.          Intentionally
Omitted.

 

1.4.          Certain
Definitions. When used herein, the following terms shall have the respective meanings indicated:

 

“Adjusted
Put Shares” shall have the meaning set forth in Section 1.2(b).

 

“Affiliate”
means, as to any Person (the “subject Person”), any other Person (a) that directly or indirectly through one
or more intermediaries controls or is controlled by, or is under direct or indirect common control with, the subject Person, (b)
that directly or indirectly beneficially owns or holds ten percent (10%) or more of any class of voting equity of the subject Person,
or (c) ten percent (10%) or more of the voting equity of which is directly or indirectly beneficially owned or held by the subject
Person. For the purposes of this definition, “control” when used with respect to any Person means the power
to direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities,
through representation on such Person’s board of directors or other management committee or group, by contract or otherwise.

 

“Amended and Restated
2013 Purchase Agreement” means the Amended and Restated 2013 Securities Purchase Agreement between the Company and certain
investors dated the date hereof.

 

“Amended
Charter” means the amendment and restatement of the Company’s Certificate of Incorporation approved by the Board
of Directors as of February 18, 2011 and by the shareholders of the Company by written consent of a majority of the issued and
outstanding Shares as of February 18, 2011.

 

“Battery Member”
has the meaning specified in Section 4.3 hereof.

 

“Board of Directors”
means the Company’s board of directors.

 

“Business”
means the consolidated business, properties, assets, operations, results of operations or financial condition of the Company and
its Subsidiaries taken as a whole.

 

“Business Day”
means any day other than a Saturday, a Sunday or a day on which the New York Stock Exchange is closed or on which banks in the
City of New York are required or authorized by law to be closed.

 

“Change of Control”
means the occurrence of any one or more of the following events: (i) the sale or other disposition to an unrelated party of all
or substantially all of the assets of the Company, in one transaction or a series of transactions (other than financing arrangements);
or (ii) a merger, consolidation or share exchange involving the Company and any other person or entity (other than for the purposes
of reincorporation), in which the Company or one of its subsidiaries is not the surviving entity, after approval of the Board of
Directors.

 

    	4

    	 

    

 

“Closing”
shall mean the Initial Closing, Additional Closing or Put Option Closing, as applicable.

 

“Closing Date”
shall mean the Initial Closing Date, Additional Closing Date or Put Option Closing Date, as applicable.

 

“Commission” means the Securities and
Exchange Commission.

 

“Common Stock” has the meaning specified
in the preamble to this Agreement.

 

“Debt”
means, as to any Person at any time: (a) all indebtedness, liabilities and obligations of such Person for borrowed money; (b) all
indebtedness, liabilities and obligations of such Person to pay the deferred purchase price of Property or services (except trade
accounts payable, accrued compensation, accrued expenses, and unearned revenue and customer deposits of such Person that, in any
such case, arise in the ordinary course of business and are not more than sixty (60) days past due); (c) all capital lease obligations
of such Person; (d) all indebtedness, liabilities and obligations of others guaranteed by such Person; (e) all indebtedness, liabilities
and obligations secured by a Lien existing on Property owned by such Person, whether or not the indebtedness, liabilities or obligations
secured thereby have been assumed by such Person or are non-recourse to such Person; (f) all reimbursement obligations of such
Person (whether contingent or otherwise) in respect of letters of credit, bankers’ acceptances, surety or other bonds and
similar instruments; and (g) all indebtedness, liabilities and obligations of such Person to redeem or retire shares of capital
stock of such Person.

 

“Disclosure Documents”
means all SEC Documents filed by the Company at least two (2) Business Days prior to the date of this Agreement via the Commission’s
Electronic Data Gathering, Analysis and Retrieval system (EDGAR) in accordance with the requirements of Regulation S-T under the
Exchange Act.

 

“Effective Date”
has the meaning set forth in the Registration Rights Agreement.

 

“Environmental Law”
means any federal, state, provincial, local or foreign law, statute, code or ordinance, principle of common law, rule or regulation,
as well as any Permit, order, decree, judgment or injunction issued, promulgated, approved or entered thereunder, relating to pollution
or the protection, cleanup or restoration of the environment or natural resources, or to the public health or safety, or otherwise
governing the generation, use, handling, collection, treatment, storage, transportation, recovery, recycling, discharge or disposal
of hazardous materials.

 

“ERISA”
means the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

 

    	5

    	 

    

 

“Execution Date”
means the date of the Original 2011 Securities Purchase Agreement.

 

“Filed Registration
Statement Effective Date” means the date on which the Company’s registration statement on either Form S-1 or Form
S-3 is declared effective by the Commission.

 

“FINRA” means Financial Industry Regulatory
Authority.

 

“GAAP”
means generally accepted accounting principles, applied on a consistent basis, as set forth in (i) opinions of the Accounting Principles
Board of the American Institute of Certified Public Accountants, (ii) statements of the Financial Accounting Standards Board and
(iii) interpretations of the Commission and the staff of the Commission. Accounting principles are applied on a “consistent
basis” when the accounting principles applied in a current period are comparable in all material respects to those accounting
principles applied in a preceding period.

 

“Governmental Authority”
means any nation or government, any state, provincial or political subdivision thereof and any entity exercising executive, legislative,
judicial, regulatory or administrative functions of or pertaining to government, including without limitation any stock exchange,
securities market or self-regulatory organization.

 

“Governmental Requirement”
means any law, statute, code, ordinance, order, rule, regulation, judgment, decree, injunction, franchise, license or other directive
or requirement of any federal, state, county, municipal, parish, provincial or other Governmental Authority or any department,
commission, board, court, agency or any other instrumentality of any of them.

 

“Intellectual Property”
means any U.S. or foreign patents, patent rights, patent applications, trademarks, trade names, service marks, brand names, logos
and other trade designations (including unregistered names and marks), trademark and service mark registrations and applications,
copyrights and copyright registrations and applications, inventions, invention disclosures, protected formulae, formulations, processes,
methods, trade secrets, computer software, computer programs and source codes, manufacturing research and similar technical information,
engineering know-how, customer and supplier information, assembly and test data drawings or royalty rights.

 

“Legally Available
Cash” shall have the meaning set forth in Section 1.2(b).

 

“Lien”
means, with respect to any Property, any mortgage, pledge, hypothecation, assignment, deposit arrangement, security interest, tax
lien, financing statement, pledge, charge, or other lien, charge, easement, encumbrance, preference, priority or other security
agreement or preferential arrangement of any kind or nature whatsoever on or with respect to such Property (including, without
limitation, any conditional sale or other title retention agreement having substantially the same economic effect as any of the
foregoing).

 

“Material Adverse
Effect” means an effect that is material and adverse to (i) the Business, (ii) the ability of the Company to perform
its obligations under this Agreement or the other Transaction Documents (as defined below) or (iii) the rights and benefits to
which an Investor is entitled under this Agreement and the other Transaction Documents.

 

    	6

    	 

    

 

“Material Contracts”
means, as to the Company, any agreement required pursuant to Item 601 of Regulation S-B or Item 601 of Regulation S-K, as applicable,
promulgated under the Securities Act to be filed as an exhibit to any report, schedule, registration statement or definitive proxy
statement filed or required to be filed by the Company with the Commission under the Exchange Act or any rule or regulation promulgated
thereunder, and any and all amendments, modifications, supplements, renewals or restatements thereof.

 

“Measurement Period” has the meaning
specified in Section 1.2(b) hereof.

 

“New Securities”
shall mean, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or
warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable
into or exercisable for such equity securities.

 

“Option”
shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.

 

“Original 2011 Securities
Purchase Agreement” has the meaning specified in the preamble to this Agreement.

 

“OTCBB” has the meaning specified in
Section 3.22 hereof.

 

“Other Securities
Purchase Agreements” means, each and jointly, the Amended and Restated 2013 Purchase Agreement and the 2015 Purchase
Agreement.

 

“Pension Plan”
means an employee benefit plan (as defined in ERISA) maintained by the Company for employees of the Company or any of its Affiliates.

 

“Permitted Liens” means the following:

 

(h)          encumbrances
consisting of easements, rights-of-way, zoning restrictions or other restrictions on the use of Real Property or imperfections
to title that do not (individually or in the aggregate) materially impair the ability of the Company to use such Property in its
businesses, and none of which is violated in any material respect by existing or proposed structures or land use;

 

(i)          Liens
for taxes, assessments or other governmental charges (including without limitation in connection with workers’ compensation
and unemployment insurance) that are not delinquent or which are being contested in good faith by appropriate proceedings, which
proceedings have the effect of preventing the forfeiture or sale of the Property subject to such Liens, and for which adequate
reserves (as determined in accordance with GAAP) have been established; and

 

(j)          Liens
of mechanics, materialmen, warehousemen, carriers, landlords or other similar statutory Liens securing obligations that are not
yet due and are incurred in the ordinary course of business or which are being contested in good faith by appropriate proceedings,
which proceedings have the effect of preventing the forfeiture or sale of the Property subject to such Liens, for which adequate
reserves (as determined in accordance with GAAP) have been established.

 

    	7

    	 

    

 

“Per Share Price”
shall mean $0.75 per Share, as adjusted for any dividend, stock split, reverse stock split, split-up or other distribution on shares
of Common Stock.

 

“Person”
means any individual, corporation, trust, association, company, partnership, joint venture, limited liability company, joint stock
company, Governmental Authority or other entity.

 

“Principal Market”
means the principal exchange or market on which the Common Stock is listed or traded.

 

“Property”
means property and/or assets of all kinds, whether real, personal or mixed, tangible or intangible (including, without limitation,
all rights relating thereto).

 

“Pro Rata Share”
means, with respect to an Investor, the ratio determined by dividing (i) the number of Shares purchased hereunder by such Investor
by (ii) the aggregate number of Shares purchased hereunder by all of the Investors.

 

“Purchase Price”
means, with respect to an Investor, the number of Shares purchased by such Investor at the Closing times the Per Share Price.

 

“Put Option Closing” has the meaning
specified in Section 1.2(a) hereof.

 

“Put Option Closing Date” has the meaning
specified in Section 1.2(c) hereof.

 

“Put Option Exercise
Notice” has the meaning specified in Section 1.2(a) hereof.

 

“Put Option Exercise
Deadline” has the meaning specified in Section 1.2(a) hereof.

 

“Put Option Termination
Event” has the meaning specified in Section 1.2(c) hereof.

 

“Put Option Trigger
Event” shall mean the occurrence of any of the following events: (i) any Change of Control of the Company, or (ii) the
sale or exclusive license of substantially all of the Company’s assets, or similar transaction, involving all or substantially
all of the Company’s assets.

 

“Put Right” has the meaning specified
in Section 1.2(a) hereof.

 

“Put Shares”
has the meaning specified in Section 1.2(a) hereof.

 

“Real Property”
has the meaning specified in Section 3.22 hereof.

 

“Registrable Securities”
has the meaning set forth for “2011 Registrable Securities” in the Registration Rights Agreement.

 

    	8

    	 

    

 

“Registration Rights
Agreement” means the 2015 Amended and Restated Registration Rights Agreement dated as of the date of this Agreement.

 

“Rule 144”
means Rule 144 under the Securities Act or any successor provision.

 

“SEC Documents” has the meaning specified
in Section 3.4 hereof.

 

“Securities” has the meaning specified
in the preamble to this Agreement.

 

“Subsequent Financing”
means any planned issuance by the Company or any of its Subsidiaries of Common Stock, common stock equivalents, indebtedness or
a combination of units thereof for cash consideration, except for public offerings of Common Stock or other securities of the Company.

 

“Subsequent Financing
Share” means a fraction, the numerator of which is the number of Shares purchased by such Investor pursuant to this Agreement
held by such Investor on the date of a Pre-Notice (as defined in Section 4.4(a)), and the denominator of which is the total number
of Shares issued to all Investors pursuant to the terms of this Agreement outstanding on the date of such Pre-Notice.

 

“Subsidiary”
means, with respect to the Company, any corporation or other entity (other than an entity having no material operations or business
during the twelve month period immediately preceding the Execution Date) of which at least a majority of the outstanding shares
of stock or other ownership interests having by the terms thereof ordinary voting power to elect a majority of the board of directors
(or Persons performing similar functions) of such corporation or entity (regardless of whether or not at the time, in the case
of a corporation, stock of any other class or classes of such corporation shall have or might have voting power by reason of the
happening of any contingency) is at the time directly or indirectly owned or controlled by the Company or one or more of its Affiliates.

 

“Termination Date”
means the first date on which there are no Warrants outstanding.

 

“Trading
Day” means any day on which the Common Stock may be purchased and sold on the Principal Market.

 

“Transaction
Documents” means, collectively, this Agreement, the Registration Rights Agreement, the Warrants, and all other agreements,
documents and other instruments executed and delivered by or on behalf of the Company or any of its officers at the Closing.

 

“2013
Investors” means collectively, the several investors party to the 2013 Purchase Agreement.

 

“2013
Purchase Agreement” means the Securities Purchase Agreement between the Company and certain investors dated January 28,
2013.

 

“2015
Investors” means collectively, the several investors party to the 2015 Purchase Agreement.

 

    	9

    	 

    

 

“2015 Purchase Agreement”
means the Securities Purchase Agreement between the Company and certain investors dated the date of this Agreement.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a stock exchange, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the stock exchange on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) the volume weighted average price of the Common
Stock for such date (or the nearest preceding date) on the OTC Bulletin Board, (c) if the Common Stock is not then listed or quoted
for trading on the OTC Bulletin Board and if prices for the Common Stock are then reported in the “Pink Sheets” published
by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent
bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected in good faith by the Investors of a majority in interest of the Shares then
outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

1.5.          Other
Definitional Provisions. All definitions contained in this Agreement are equally applicable to the singular and plural forms
of the terms defined. The words “hereof’, “herein” and “hereunder” and words of similar import
referring to this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement.

 

2.           Representations
and Warranties of Each Investor. Each Investor (with respect to itself only) hereby represents and warrants to the Company
and agrees with the Company that, as of the Execution Date and as of the Closing Date:

 

2.1           Authorization;
Enforceability. Such Investor is duly and validly organized, validly existing and in good standing under the laws of the jurisdiction
of its incorporation or organization as set forth below such Investor’s name on the signature page hereof with the requisite
corporate power and authority to purchase the Shares and Warrant to be purchased by it hereunder and to execute and deliver this
Agreement and the other Transaction Documents to which it is a party. This Agreement constitutes, and upon execution and delivery
thereof, each other Transaction Document to which such Investor is a party will constitute, such Investor’s valid and legally
binding obligation, enforceable in accordance with its terms, subject to (i) applicable bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium or other similar laws of general application relating to or affecting the enforcement of creditors’
rights generally and (ii) general principles of equity.

 

2.2           Accredited
Investor. Such Investor (i) is an “accredited investor” as that term is defined in Rule 501 of Regulation D, (ii)
is acquiring the Securities in the ordinary course of its business, solely for its own account, and not with a view to the public
resale or distribution of all or any part thereof, except pursuant to sales that are registered under the Securities Act or are
exempt from the registration requirements of, the Securities Act and does not have any agreement or understanding with any person
to distribute any of the Securities; provided, however, that, in making such representation, such Investor does not agree
to hold the Securities for any minimum or specific term and reserves the right to sell, transfer or otherwise dispose of the Securities
at any time in accordance with the provisions of this Agreement and with Federal and state securities laws applicable to such sale,
transfer or disposition.

 

    	10

    	 

    

 

2.3           Information.
The Company has, prior to the Execution Date, provided such Investor with information regarding the business, operations and financial
condition of the Company and has, prior to the Execution Date, granted to such Investor the opportunity to ask questions of and
receive satisfactory answers from representatives of the Company, its officers, directors, employees and agents concerning the
Company and materials relating to the terms and conditions of the purchase and sale of the Securities hereunder, as such Investor
deems relevant in making an informed decision with respect to its investment in the Securities. Such Investor is able to bear the
economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.
Neither such information nor any other investigation conducted by such Investor or any of its representatives shall modify, amend
or otherwise affect such Investor’s right to rely on the Company’s representations and warranties contained in this
Agreement.

 

2.4           Limitations
on Disposition. Such Investor acknowledges that, except as provided in the Registration Rights Agreement, the Securities have
not been and are not being registered under the Securities Act and may not be transferred or resold without registration under
the Securities Act or unless pursuant to an exemption therefrom.

 

2.5           Legend.
Such Investor understands that the certificates representing the Securities may bear at issuance a restrictive legend in substantially
the following form:

 

(a)          “The
securities represented by this certificate have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), or the securities laws of any state, and may not be offered, transferred, pledged, hypothecated, sold or otherwise
disposed of unless a registration statement under the Securities Act and applicable state securities laws shall have become effective
with regard thereto, or an exemption from registration under the Securities Act and applicable state securities laws is available
in connection with such offer or sale.”

 

2.6           Reliance
on Exemptions. Such Investor understands that the Securities are being offered and sold to it in reliance upon specific exemptions
from the registration requirements of U.S. federal and state securities laws and that the Company is relying upon the truth and
accuracy of the representations and warranties of such Investor set forth in this Section 2 in order to determine the availability
of such exemptions and the eligibility of such Investor to acquire the Securities.

 

2.7           Non-Affiliate
Status; Common Stock Ownership. Other than Battery, such Investor is not an Affiliate of the Company or of any other Investor
and is not acting in association or concert with any other Person in regard to its purchase of the Securities or otherwise in respect
of the Company. Such Investor’s investment in the Securities is not for the purpose of acquiring, directly or indirectly,
control of, and it has no intent to acquire or exercise control of, the Company or to influence the decisions or policies of the
Board of Directors.

 

    	11

    	 

    

 

3.          Representations
and Warranties of the Company. The Company hereby represents and warrants to each Investor that, except as expressly set forth
on the disclosure schedules to this Agreement, as of the Execution Date and as of the Closing Date:

 

3.1           Organization,
Good Standing and Qualification. The Company and each of its Subsidiaries is an entity duly organized, validly existing and
in good standing under the laws of the jurisdiction under which it is incorporated, and has all requisite corporate power and authority
to conduct its business as currently conducted and to execute, deliver and perform all of its obligations under this Agreement
and to consummate the transactions contemplated hereby. The Company and each of its subsidiaries is qualified to do business as
a foreign corporation in each jurisdiction where failure to be so qualified could, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.

 

3.2           Authorization;
Consents. The Company has the requisite corporate power and authority to enter into and perform its obligations under the Transaction
Documents, including, without limitation, its obligations to issue and sell the Securities to the Investors in accordance with
the terms hereof and thereof, and to issue the Warrant Shares upon exercise of the Warrants. All corporate action on the part of
the Company by its officers, directors and stockholders necessary for the authorization, execution and delivery of, and the performance
by the Company of its obligations under, the Transaction Documents has been taken, and no further consent or authorization of the
Company, its Board of Directors, stockholders, any Governmental Authority or organization (other than such approval as may be required
under the Securities Act and applicable state securities laws in respect of the Registration Rights Agreement), or any other person
or entity is required (pursuant to any rule of FINRA or otherwise).

 

3.3           Due
Execution; Enforceability. This Agreement has been and, at or prior to the Closing, each other Transaction Document to be delivered
at the Closing will be, duly executed and delivered by the Company. This Agreement constitutes and, upon the execution and delivery
thereof by the Company, each other Transaction Document will constitute the valid and legally binding obligation of the Company,
enforceable against it in accordance with its terms, subject to (i) applicable bankruptcy, insolvency, fraudulent transfer, moratorium,
reorganization or other similar laws of general application relating to or affecting the enforcement of creditors’ rights
generally and (ii) general principles of equity.

 

    	12

    	 

    

 

3.4           Disclosure
Documents; Agreements; Financial Statements; Other Information. The Company is subject to the reporting requirements of the
Exchange Act and has filed with the Commission all reports, schedules, registration statements and definitive proxy statements
that the Company was required to file with the Commission during the preceding twelve calendar months (collectively, the “SEC
Documents”). The Company is not aware of any event occurring or expected to occur on or prior to the Closing Date (other
than the transactions effected hereby and quarterly releases of financial results) that would require the filing of, or with respect
to which the Company intends to file, a Form 8-K after the Closing. Each SEC Document, as of the date of the filing thereof with
the Commission (or if amended or superseded by a filing prior to the Execution Date, then on the date of such amending or superseding
filing), complied in all material respects with the requirements of the Securities Act or Exchange Act, as applicable, and the
rules and regulations promulgated thereunder and, as of the date of such filing (or if amended or superseded by a filing prior
to the Execution Date, then on the date of such filing), such SEC Document (including all exhibits and schedules thereto and documents
incorporated by reference therein) did not contain an untrue statement of material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not
misleading. All documents required to be filed as exhibits to the SEC Documents have been filed as required. Except as set forth
in the Disclosure Documents, the Company has no liabilities, contingent or otherwise, other than liabilities incurred in the ordinary
course of business which, under GAAP, are not required to be reflected in the financial statements included in the Disclosure Documents
and which, individually or in the aggregate, are not material to the business or financial condition of the Company. As of their
respective dates, the financial statements of the Company included in the SEC Documents have been prepared in accordance with GAAP
(except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim
statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material
respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the
periods then ended (subject, in the case of unaudited statements, to normal year-end adjustments).

 

3.5           Capitalization;
Debt Schedule. The capitalization of the Company as of the date hereof, including its authorized capital stock, the number
of shares issued and outstanding, the number of shares issuable and reserved for issuance pursuant to the Company’s stock
option plans and agreements, the number of shares issuable and reserved for issuance pursuant to securities (other than the Warrants)
exercisable for, or convertible into or exchangeable for any shares of Common Stock and the number of shares initially to be reserved
for issuance upon exercise of the Warrants, is set forth on Schedule 3.5 hereto. All issued and outstanding shares of capital stock
of the Company have been, or upon issuance will be, validly issued, fully paid and non-assessable. No shares of the capital stock
of the Company were issued in violation of preemptive rights or any other similar rights of security holders of the Company or
any Liens created by or through the Company. Except as disclosed on Schedule 3.5 or as contemplated herein, there are no outstanding
preemptive rights, rights of first refusal, shareholder rights, options, warrants, scrip, rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities or rights convertible into or exercisable or exchangeable for, any shares
of capital stock of the Company, or arrangements by which the Company is or may become (as a result of the transactions contemplated
hereby or the other Transaction Documents or otherwise) bound to issue additional shares of capital stock of the Company (whether
pursuant to anti-dilution, “reset” or other similar provisions). Except as described on Schedule 3.5 hereto, the Company
has no material Debt outstanding as of the date hereof.

 

3.6           Due
Authorization; Valid Issuance. The Shares and Warrants are duly authorized and, when issued, sold and delivered in accordance
with the terms hereof, (i) the Shares and Warrants will be duly and validly issued, and the Shares will be fully paid and nonassessable;
in each case, free and clear of any Liens imposed by or through the Company, and (ii) assuming the accuracy of each Investor’s
representations in this Agreement, the Shares and Warrants will be issued, sold and delivered in compliance with all applicable
Federal and state securities laws. The Warrant Shares are duly authorized and reserved for issuance and, when issued in accordance
with the terms of the Warrants, will be duly and validly issued, fully paid and nonassessable, free and clear of any Liens imposed
by or through the Company and, assuming the accuracy of each Investor’s representations in this Agreement at the time of
exercise, will be issued, sold and delivered in compliance with all applicable Federal and state securities laws.

 

    	13

    	 

    

 

3.7          No
Conflict with Other Instruments. The Company is not in violation of any provisions of its charter, bylaws or any other governing
document or in default (and no event has occurred which, with notice or lapse of time or both, would constitute a default) under
any provision of any instrument or contract to which it is a party or by which it or any of its Property is bound, or in violation
of any provision of any Governmental Requirement applicable to it, except for any violation or default under any such instrument
or contract or any violation of any provision of a Governmental Requirement that, in either such case, has not had or would not
reasonably be expected to have a Material Adverse Effect (any such violation or default being referred to herein as a “Current
Violation”). Provided that the Amended Charter is duly filed with the Secretary of State of Delaware, the (i) execution,
delivery and performance of this Agreement and the other Transaction Documents, and (ii) consummation of the transactions contemplated
hereby and thereby (including without limitation, the issuance of the Shares and the Warrants and the reservation for issuance
and issuance of the Warrant Shares) will not result in any violation of any provisions of the Company’s charter, Bylaws or
any other governing document or in a default under any provision of any instrument or contract to which it is a party or by which
it or any of its Property is bound, or in violation of any provision of any Governmental Requirement applicable to the Company
or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under any such
provision, instrument or contract or an event which results in the creation of any Lien upon any assets of the Company.

 

3.8          Financial
Condition; Taxes; Litigation.

 

(a)          The
Company’s financial condition is, in all material respects, as described in the Disclosure Documents, except for changes
in the ordinary course of business and normal year-end adjustments that are not, in the aggregate, materially adverse to the business
or financial condition of the Company. There has been no (i) material adverse change to the Company’s business, operations,
properties, financial condition, or results of operations since the date of the Company’s most recent audited financial statements
contained in the Disclosure Documents or (ii) change by the Company in its accounting principles, policies and methods except as
required by changes in GAAP or applicable law.

 

(b)          The
Company (i) has prepared in good faith and duly and timely filed all tax returns required to be filed by it and such returns are
complete and accurate in all material
respects and (ii) has paid all taxes required to have been paid by it, except for taxes which it reasonably disputes in good faith
or the failure of which to pay has not had or would not reasonably be expected to have a Material Adverse Effect, and has no liability
with respect to accrued taxes in excess of the amounts that are described as accrued in the most recent financial statements included
in the Disclosure Documents.

 

    	14

    	 

    

 

(c)          Except
as described in Schedule 3.8(c), the Company is not the subject of any pending or, to the Company’s knowledge, threatened
inquiry, investigation or administrative or legal proceeding by the Internal Revenue Service, the taxing authorities of any state
or local jurisdiction (other than with respect to taxes which it reasonably disputes in good faith or the failure of which to pay
has not had or would not reasonably be expected to have a Material Adverse Effect), the Commission, FINRA, any state securities
commission or other Governmental Authority.

 

(d)          Except
as described in Schedule 3.8(d), there is no material claim, litigation or administrative proceeding pending or, to the Company’s
knowledge, threatened or contemplated, against the Company or, to the Company’s knowledge, against any officer, director
or employee of the Company in connection with such person’s employment therewith. The Company is not a party to or subject
to the provisions of, any order, writ, injunction, judgment or decree of any court or Governmental Authority which has had or would
reasonably be expected to have a Material Adverse Effect.

 

3.9          Acknowledgement
of Dilution. The Company acknowledges that the issuance of Warrant Shares upon exercise of the Warrants may result in dilution
of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions. The Company further
acknowledges that its obligation to issue Warrant Shares upon exercise of the Warrants in accordance with the terms of the Warrants,
is unconditional (other than with respect to the conditions set forth in the Warrants) regardless of the effect of any such dilution.

 

3.10        Intellectual
Property. Except as set forth in Schedule 3.10:

 

(a)          The
Company owns, free and clear of claims or rights or any other Person, with full right to use, sell, license, sublicense, dispose
of, and bring actions for infringement of, or, to the knowledge of the Company, has acquired licenses or other rights to use, all
Intellectual Property necessary for the conduct of its business as presently conducted (other than with respect to software which
is generally commercially available and not used or incorporated into the Company’s products and open source software which
may be subject to one or more “general public” licenses). All works that are used or incorporated into the Company’s
services, products or services or products actively under development and which is proprietary to the Company was developed by
or for the Company by the current or former employees, consultants or independent contractors of the Company or its predecessors
in interest or purchased or licensed by the Company or its predecessors in interest.

 

(b)          The
business of the Company as presently conducted and the production, marketing, licensing, use and servicing of any products or services
of the Company do not, to the knowledge of the Company, infringe or conflict with any patent, trademark, copyright, or trade secret rights of any third parties or any other Intellectual
Property of any third parties in any material respect. The Company has not received written notice from any third party asserting
that any Intellectual Property owned or licensed by the Company, or which the Company otherwise has the right to use, is invalid
or unenforceable by the Company and, to the Company’s knowledge, there is no valid basis for any such claim (whether or not
pending or threatened).

 

    	15

    	 

    

 

(c)          No
claim is pending or, to the Company’s knowledge, threatened against the Company nor has the Company received any written
notice or other written claim from any Person asserting that any of the Company’s present or contemplated activities infringe
or may infringe in any material respect any Intellectual Property of such Person and the Company is not aware of any infringement
by any other Person of any material rights of the Company under any Intellectual Property Rights.

 

(d)          All
licenses or other agreements under which the Company is granted Intellectual Property (excluding licenses to use software utilized
in the Company’s internal operations and which is generally commercially available) are in full force and effect and, to
the Company’s knowledge, there is no material default by any party thereto. The Company has no reason to believe that the
licensors under such licenses and other agreements do not have and did not have all requisite power and authority to grant the
rights to the Intellectual Property purported to be granted thereby.

 

(e)          All
licenses or other agreements under which the Company has granted rights to Intellectual Property to others (including all end-user
agreements) since January 1, 2008, are in full force and effect, unless otherwise terminated in accordance with the terms of such
licenses or arrangements, there has been no material default by the Company thereunder and, to the Company’s knowledge, there
is no material default by any other party thereto.

 

(f)          The
Company has taken all steps required in accordance with commercially reasonable business practice to establish and preserve its
ownership in its owned Intellectual Property and to keep confidential all material technical information developed by or belonging
to the Company which has not been patented or copyrighted. The Company is not making any material unlawful use of any Intellectual
Property of any other Person, including, without limitation, any former employer of any past or present employees of the Company.
To the Company’s knowledge, neither the Company nor any of its employees has any agreements or arrangements with former
employers of such employees relating to any Intellectual Property of such employers, which materially interfere or conflict with
the performance of such employee’s duties for the Company or result in any former employers of such employees having any
rights in, or claims on, the Company’s Intellectual Property. Each current and former employee of the Company has executed
agreements regarding confidentiality, proprietary information and assignment of inventions and copyrights to the Company, each
independent contractor or consultant of the Company has executed agreements regarding confidentiality and proprietary information,
and the Company has not received written notice that any employee, consultant or independent contractor is in violation of any
agreement or in breach of any agreement or arrangement with former or present employers relating to proprietary information or
assignment of inventions. Without limiting the foregoing: (i) the Company has taken reasonable security measures to guard against
unauthorized disclosure or use of any of its Intellectual Property; and the Company has no reason to believe that any Person (including,
without limitation, any former employee or consultant of the Company) has unauthorized possession of any of its Intellectual Property,
or any part thereof, or that any Person has obtained unauthorized access to any of its Intellectual Property. The Company is in
compliance in all material respects with its obligations pursuant to all agreements relating to Intellectual Property rights that
are the subject of licenses granted by third parties, except for any non-compliance that has not had or would not reasonably be
expected to have a Material Adverse Effect.

 

    	16

    	 

    

 

3.11         Registration
Rights; Rights of Participation. Except as described on Schedule 3.11 hereto, the Company has not granted or agreed to grant
to any person or entity any rights (including “piggy-back” registration rights) to have any securities of the Company
registered with the Commission or any other governmental authority which has not been satisfied in full prior or waived to the
date hereof.

 

3.12         Fees.
Except as contemplated by Section 7.11 hereof and as set forth on Schedule 3.12 or disclosed in writing to the Investor by the
Company, the Company is not obligated to pay any compensation or other fee, cost or related expenditure to any underwriter, broker,
agent or other representative in connection with the transactions contemplated hereby. The Company will indemnify and hold harmless
each Investor from and against any claim by any person or entity alleging that, as a result of any agreement or arrangement between
such Person and the Company, such Investor is obligated to pay any such compensation, fee, cost or related expenditure in connection
with the transactions contemplated hereby or the other Transaction Documents.

 

3.13         Solicitation;
Other Issuances of Securities. Neither the Company nor any of its Subsidiaries or Affiliates, nor any person acting on its
or their behalf, (i) has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D)
in connection with the offer or sale of the Securities, or (ii) has, directly or indirectly, made any offers or sales of any security
or the right to purchase any security, or solicited any offers to buy any security or any such right, under circumstances that
would require registration of the Securities under the Securities Act.

 

3.14         Foreign
Corrupt Practices. Neither the Company, nor to the Company’s knowledge any director, officer, agent, employee or other
person acting on behalf of the Company, has (i) used any corporate funds for any unlawful contribution, gift, entertainment or
other unlawful expenses relating to political activity, (ii) made any direct or indirect unlawful payment to any foreign or domestic
government official or employee (including without limitation any bribe, rebate, payoff, influence payment, kickback or other unlawful
payment), or (iii) violated any provision of the Foreign Corrupt Practices Act of 1977, as amended.

 

3.15         Key
Employees. Each of the Company’s executive officers (as defined in Rule 501(f) of the Securities Act) (each, a “Key
Employee”) is currently serving in the capacity described in the Disclosure Documents. The Company has no knowledge of
any fact or circumstance (including without limitation (i) the terms of any agreement to which such person is a party or any litigation
in which such person is or may become involved and (ii) any illness or medical condition that could reasonably be expected to result
in the disability or incapacity of such person) that would limit or prevent any such person from serving in such capacity on a
full-time basis
in the foreseeable future, or of any intention on the part of any such person to limit or terminate his or her employment with
the Company.

 

3.16         Employee
Matters. There is no strike, labor dispute or union organization activities pending or, to the knowledge of the Company, threatened
between it and its employees. No employees of the Company belong to any union or collective bargaining unit. The Company has complied
in all material respects with all applicable federal and state equal opportunity and other laws related to employment.

 

    	17

    	 

    

 

3.17         Environment.
To the Company’s knowledge, the Company does not have any current liability under any Environmental Law, nor, to the knowledge
of the Company, do any factors exist that are reasonably likely to give rise to any such liability that, individually or in the
aggregate, has had or would reasonably be expected to have a Material Adverse Effect. To the Company’s knowledge, the Company
has not violated any Environmental Law applicable to it now or previously in effect, other than such violations or infringements
that, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect.

 

3.18         ERISA.
Except as described on Schedule 3.18, the Company does not maintain or contribute to, or have any obligation under, any Pension
Plan. The Company is in compliance in all material respects with the presently applicable provisions of ERISA and the United States
Internal Revenue Code of 1986, as amended, with respect to each Pension Plan except in any such case for any such matters that,
individually or in the aggregate, have not had, and would not reasonably be expected to have, a Material Adverse Effect.

 

3.19         Insurance.
The Company maintains insurance in such amounts and covering such losses and risks as the Company believes to be reasonably prudent
in relation to the businesses in which the Company is engaged. No notice of cancellation has been received for any of such policies
and the Company reasonably believes that is in compliance with all of the terms and conditions thereof The Company has no reason
to believe that it will not be able to renew any existing insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue doing business as currently conducted without a significant increase
in cost, other than normal increases in the industry. Without limiting the generality of the foregoing, the Company maintains Director’s
and Officer’s insurance in an amount deemed to be reasonable and appropriate by the Company’s Board of Directors.

 

3.20         Property.
The Company does not own any real property. The Company has good and marketable title to all personal Property owned by it which,
in each such case free and clear of all Liens except for Permitted Liens and except for such Liens which, individually and together
with all other Liens (including without limitation Permitted Liens) do not have, and cannot reasonably be expected to have, a Material
Adverse Effect. Any Property held under lease by the Company is held by it under valid, subsisting and enforceable leases with
such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such Property by
the Company.

 

3.21         Regulatory
Permits. The Company possesses all material certificates, authorizations and permits issued by the appropriate federal, state
or foreign regulatory authorities necessary to conduct its businesses other than where the failure to possess such certificates,
authorizations or permits, individually or in the aggregate, has not had and would not reasonably be expected to have a Material
Adverse Effect. The Company has not received any notice or otherwise become aware of any proceedings, inquiries or investigations
relating to the revocation or modification of any such certificate, authorization or permit.

 

    	18

    	 

    

 

3.22         Exchange
Act Registration; Listing. Exchange Act Registration; Listing. The Company files supplementary and periodic information, documents,
and reports pursuant to Section 15(d) of the Exchange Act. The Company’s Common Stock is registered pursuant to Section 12(g)
of the Exchange Act and is traded over-the-counter and quoted on the over-the-counter Bulletin Board QB or QX Markets (collectively,
“OTCBB”). The Company has taken no action designed to, or which, to the knowledge of the Company, would reasonably
be expected to have the effect of, terminating the registration of the Common Stock under the Exchange Act or ceasing the trading
of the Common Stock or its quoting on the OTCBB

 

3.23         Investment
Company Status. The Company is not, and immediately after receipt of payment for the Shares and the Warrants issued under this
Agreement will not be, an “investment company” or an entity “controlled” by an “investment
company” within the meaning of the Investment Company Act of 1940, as amended (the “Investment Company Act”),
and shall conduct its business in a manner so that it will not become subject to the Investment Company Act.

 

3.24         Transfer
Taxes. No stock transfer or other taxes (other than income taxes) are required to be paid in connection with the issuance and
sale of any of the Securities, other than such taxes for which the Company has established appropriate reserves and intends to
pay in full on or before the Closing.

 

3.25         Sarbanes-Oxley
Act; Internal Controls and Procedures. The Company is in material compliance with any and all applicable requirements of the
Sarbanes-Oxley Act of 2002 and any and all applicable rules and regulations promulgated by the SEC thereunder that are effective
as of the date hereof. The Company maintains internal accounting controls, policies and procedures, and such books and records
as are reasonably designed to provide reasonable assurance that (i) all transactions to which the Company is a party or by which
its properties are bound are effected by a duly authorized employee or agent of the Company, supervised by and acting within the
scope of the authority granted by the Company’s senior management; (ii) the recorded accounting of the Company’s consolidated
assets is compared with existing assets at regular intervals; and (iii) all transactions to which the Company is a party, or by
which its properties are bound, are recorded (and such records maintained) in accordance with all Governmental Requirements and
as may be necessary or appropriate to ensure that the financial statements of the Company are prepared in accordance with GAAP.

 

3.26         Embargoed
Person. None of the funds or other assets of the Company shall constitute property of, or shall be beneficially owned,
directly or indirectly, by any person subject to trade restrictions under United States law, including, but not limited to,
the International Emergency Economic Powers Act, 50 U.S.C. § 1701 et seq., the Trading with the 
Enemy Act, 50 U.S.C. App. 1 et seq., and any Executive Orders or regulations promulgated under any such United States
laws (each, an “Embargoed Person”), with the result that the investments evidenced by the Securities are
or would be in violation of law. No Embargoed Person shall have any interest of any nature whatsoever in the Company with the
result that the investments evidenced by the Securities are or would be in violation of law. None of the funds or other
assets of the Company shall be derived from any unlawful activity with the result that the investments evidenced by the
Securities are or would be in violation of law.

 

    	19

    	 

    

 

3.27         Solvency.
As of the Execution Date and as of the Closing Date, (i) the fair saleable value of the Company’s assets exceeds the amount
that will be required to be paid on or in respect of the Company’s existing Debt as such Debt matures or is otherwise payable;
(ii) the Company’s assets do not constitute unreasonably small capital to carry on its business for the current fiscal year
as now conducted and as proposed to be conducted taking into account the current and projected capital requirements of the business
conducted by the Company and projected capital availability; and (iii) the current cash flow of the Company, together with the
proceeds the Company would receive upon liquidation of its assets, after taking into account all anticipated uses of such amounts,
would be sufficient to pay all Debt when such Debt is required to be paid. The Company has no knowledge of any facts or circumstances
which lead it to believe that it will be required to file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction, and has no present intention to so file.

 

3.28         Transactions
with Interested Persons. Except as set forth in the Disclosure Documents, no officer, director or employee of the Company is
or has made any arrangements with the Company to become a party to any transaction with the Company (other than for services as
employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services
to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer,
director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee
has a substantial interest or is an officer, director, trustee or partner.

 

3.29        Customers
and Suppliers. Except as set forth in the Disclosure Documents, the relationships of the Company with its customers and suppliers
are maintained on commercially reasonable terms. To the Company’s knowledge, no customer or supplier of the Company has any
plan or intention to terminate its agreement with the Company, which termination would reasonably be expected to have a Material
Adverse Effect.

 

3.30         FDA
Matters and Clinical Trials.

 

(a)          The
Company has not received any notices or correspondence from any federal, state, local or foreign regulatory body that
regulates the types of matters subject to the jurisdiction of the U.S. Food and Drug Administration (“Health
Authorities”) which have not been resolved requiring or threatening the termination, suspension or modification of
any animal studies, preclinical tests or clinical trials conducted by or on behalf of the Company or in which the Company has
participated that are described in the Disclosure Documents or the results of which are referred to in the Disclosure
Documents. To the knowledge of the Company, the currently pending clinical trials, studies and other preclinical tests
conducted by or on behalf of the Company and that are described in the Disclosure 
Documents or the results of which are referred to in the Disclosure Documents, are being conducted in accordance with
experimental protocols, procedures and controls generally used by qualified experts in the preclinical or clinical study of
new drugs.

 

(b)          The
Company has no knowledge of any adverse event that has resulted from any of such studies, tests or trials that was not disclosed
as required to any Health Authority.

 

    	20

    	 

    

 

3.31         Full
Disclosure. The representations, warranties and written statements contained in this Agreement and the other Transaction Documents
and in the certificates, exhibits and schedules delivered to such Investor by the Company pursuant to this Agreement and the other
Transaction Documents and in connection with such Investor’s due diligence investigation of the Company, do not contain any
untrue statement of a material fact, and do not omit to state a material fact required to be stated therein or necessary in order
to make such representations, warranties or statements not misleading in light of the circumstances under which they were made.
Neither the Company nor any Person acting on its behalf or at its direction has provided such Investor with material non-public
information. Following the filing of the Current Report on Form 8-K in accordance with Section 4.1(c) hereof, to the Company’s
knowledge, such Investor will not possess any material non-public information concerning the Company. The Company acknowledges
that such Investor is relying on the representations, acknowledgments and agreements made by the Company in this Section 3.31 and
elsewhere in this Agreement in making trading and other decisions concerning the Company’s securities.

 

3.32         No
Other Agreements. The Company has not, directly or indirectly, entered into any agreement with or granted any right to any
Investor relating to the terms or conditions of the transactions contemplated by the Transaction Documents, except as expressly
set forth in the Transaction Documents.

 

4.          Covenants
of the Company and Each Investor.

 

4.1           The
Company agrees with each Investor that the Company will:

 

(a)          file
a Form D with respect to the Securities issued at the Closing as and when required under Regulation D and provide a copy thereof
to such Investor promptly after such filing;

 

(b)          take
such action as the Company reasonably determines upon the advice of counsel is necessary to qualify the Shares and Warrants for
sale under applicable state or “blue-sky” laws or obtain an exemption therefrom, and shall promptly provide evidence
of any such action to such Investor at such Investor’s request; and

 

(c)          on
or prior to 5:00 p.m. (eastern time) on the fourth Business Day following the Execution Date, file with the Commission a Current
Report on Form 8-K disclosing the material terms of this Agreement and the other Transaction Documents and the transactions contemplated
hereby and thereby, including as exhibits this Agreement and the other Transaction Documents; provided, however, that each
Investor shall have a reasonable opportunity to review and comment on any such Form 8-K prior to the issuance or filing thereof. Thereafter, the Company shall timely file any filings and notices required by
the Commission or applicable law with respect to the transactions contemplated hereby;

 

(d)          maintain
its corporate existence in good standing;

 

(e)          maintain,
keep and preserve all of its Properties necessary in the proper conduct of its businesses in good repair, working order and condition
(ordinary wear and tear excepted) and make all necessary repairs, renewals and replacements and improvements thereto, except where
the failure to do so would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;

 

    	21

    	 

    

 

(f)          pay
or discharge before becoming delinquent (a) all taxes, levies, assessments and governmental charges imposed on it or its income
or profits or any of its Property and (b) all lawful claims for labor, material and supplies, which, if unpaid, might become a
Lien upon any of its Property, except where the failure to do so would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect; provided, however, that the Company shall not be required to pay or discharge any
tax, levy, assessment or governmental charge, or claim for labor, material or supplies, whose amount, applicability or validity
is being contested in good faith by appropriate proceedings being diligently pursued and for which appropriate reserves have been
established under GAAP;

 

(g)          comply
with all Governmental Requirements applicable to the operation of its business, except for instances of noncompliance that would
not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;,

 

(h)          comply
with all agreements, documents and instruments binding on it or affecting its Properties or business, including, without limitation,
all Material Contracts, except for instances of noncompliance that would not reasonably be expected to have, individually or in
the aggregate, a Material Adverse Effect;

 

(i)          provide
each Investor with copies of all materials sent to its stockholders, in each such case at the same time as delivered to such stockholders;

 

(j)          timely
file with the Commission all reports required to be filed pursuant to the Exchange Act and refrain from terminating its status
as an issuer required by the Exchange Act to file reports thereunder even if the Exchange Act or the rules or regulations thereunder
would permit such termination;

 

(k)          until
the earlier of (A) Effective Date of the Registration Statement and (B) the date upon which all Investors are able to sell Shares
without volume or manner of sale limitations under Rule 144, take commercially reasonable steps to restrict each of the Company’s
Chief Executive Officer, President and Chief Financial Officer (each, a “Specified Employee”) from selling shares
of Common Stock; and

 

(l)          use
commercially reasonable efforts to maintain adequate insurance coverage (including D&O insurance) for the Company and each
Subsidiary.

 

4.2          Voting
Rights. The Company agrees that it shall not approve of or give effect to any of the following actions without the written
consent of Battery, provided, however, that the Company shall not be required to seek the written consent of Battery in
the event that Battery has sold greater than or equal to twenty-five percent (25%) of the Shares it purchases on the Closing Date
(“Battery Threshold Amount”):

 

(a)          alter
or change the rights, preferences or privileges of the Put Option;

 

(b)          other
than the repurchase of up to 2,000,000 Shares from a Company director from time to time, , purchase, redeem or otherwise acquire
any of (i) the Company’s equity securities (including warrants, options and other rights to acquire equity securities) or
(ii) the Securities, other than (A) a repurchase by the Company at the lower of cost or the fair market value pursuant to existing
agreements, (B) the purchase of capital stock from certain stockholders approved by the Investors, (C) pursuant to an exercise
of the Put Right or the put rights granted under the Other Securities Purchase Agreements or (D) the contemplated option exchange
disclosed in the disclosure schedules to the 2015 Purchase Agreement;

 

    	22

    	 

    

 

(c)          liquidate,
dissolve or wind-up the business and affairs of the Company or consent to any of the foregoing; and

 

(d)          merge
or consolidate with another corporation or entity in which the holders of the Company’s voting equity securities immediately
prior to the transaction own, directly or indirectly, fifty percent (50%) or less of the voting securities of the surviving corporation
unless (i) the consideration for the merger or consolidation is in the form of a cash offer or marketable securities that are registered,
saleable and listed on the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock
Exchange (ii) the average daily trading volume of the Common Stock during the Measurement Period immediately preceding the closing
of such merger or consolidation is equal to or greater than $1,000,000 and (iii) the purchase price per share is equal to or greater
than two hundred fifty percent (250%) of the Per Share Price.

 

4.3           Board
Representation. The Company shall be obligated to present one nominee nominated by Battery to become a member of the Company’s
Board (the “Battery Member”) either through an action by written consent or through the vote of the Company’s
stockholders at the next meeting of the Company’s stockholders, which shall be held no later than three (3) months after
the date of this Agreement; provided, however, that the Company shall no longer be obligated to nominate the Battery Member
in the event that Battery has sold the Battery Threshold Amount.

 

4.4           No
Participation Rights. Each Investor has declined to exercise such Investor’s participation right set forth in the Original
2011 Securities Purchase Agreement with respect to either the transaction effected pursuant to the 2013 Purchase Agreement or the
Company’s issuance of convertible promissory notes on December 1, 2014, and thus no longer has any participation right with
respect to either the transaction contemplated by the 2015 Purchase Agreement or future financings of the Company.

 

4.5           Reservation
of Common Stock. The Company shall, on the Closing Date, have authorized and reserved for issuance to the Investors free from
any preemptive rights, and shall keep available at all times during which any Warrants are outstanding, a number of shares of Common
Stock (the “Reserved Amount”) that, on the Closing Date, is not less than one hundred percent (100%) of the number of Warrant Shares issuable upon exercise of
all of the Warrants issued at the Closing, without regard to any limitation or restriction on such conversion or exercise that
may be set forth in the Warrants. The Reserved Amount shall be allocated in accordance with each Investor’s Pro Rata Share.
In the event that an Investor shall sell or otherwise transfer any of such Investor’s Warrants, each transferee shall be
allocated a pro rata portion of such transferor’s Reserved Amount. Any portion of the Reserved Amount allocated to
any Investor or other Person which no longer holds any Warrants shall be reallocated to the remaining Investors pro rata based
on the number of Registrable Securities held by such Investors at such time. In the event that the Reserved Amount is insufficient
at any time to cover one hundred percent 100% of the Registrable Securities issuable upon the exercise of the Warrants (without
regard to any restriction on such conversion or exercise), the Company shall take such action (including without limitation holding
a meeting of its stockholders) to increase the Reserved Amount to cover 100% of the Registrable Securities issuable upon such conversion
and exercise, such increase to be effective not later than the thirtieth (30th) day (or sixtieth (60th) day, in the event stockholder
approval is required for such increase) following the Company’s receipt of written notice of such deficiency. While any Warrants
are outstanding, the Company shall not reduce the Reserved Amount without obtaining the prior written consent of each Investor
then holding Warrants.

 

    	23

    	 

    

 

4.6           Use
of Proceeds. The Company shall use the proceeds from the sale of the Shares and Warrants for general business purposes; provided,
that the Company shall not use any of such proceeds (i) to pay any dividend or make any distribution on any of its securities,
or (ii) to repay any loan made to or incurred by any Key Employee or any other officer or director or Affiliate of the Company.

 

4.7           Use
of Investor Name. Except as may be required by applicable law and/or this Agreement, the Company shall not use, directly or
indirectly, any Investor’s name or the name of any of its Affiliates in any advertisement, announcement, press release or
other similar communication unless it has received the prior written consent of any Investor for the specific use contemplated
or as otherwise required by applicable law or regulation.

 

4.8           Company’s
Instructions to Transfer Agent. . Certificates evidencing the Shares and Warrant Shares shall not contain any legend (i) while
a registration statement (including the Registration Statement) covering the resale of such security is effective under the Securities
Act, (ii) following any sale of such Shares or Warrant Shares pursuant to Rule 144, (iii) if such Shares or Warrant Shares are
eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information
required under Rule 144 as to such Shares and Warrant Shares and without volume or manner-of-sale restrictions, or (iv) if such
legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly
after the Effective Date if required by the Transfer Agent to effect the removal of the legend hereunder. If all or any portion
of a Warrant is exercised at a time when there is an effective registration statement to cover the resale of the Warrant Shares,
or if such Shares or Warrant Shares may be sold under Rule 144 and the Company is then in compliance with the current public information
required under Rule 144, or if the Shares or Warrant Shares may be sold under Rule 144 without the requirement for the Company
to be in compliance with the current
public information required under Rule 144 as to such Shares or Warrant Shares or if such legend is not otherwise required under
applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the
Commission) then such Warrant Shares shall be issued free of all legends. The Company agrees that following the Effective Date
or at such time as such legend is no longer required under this Section 4.8, it will, no later than three Trading Days following
the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Shares or Warrant Shares, as the
case may be, issued with a restrictive legend (such third Trading Day, the “Legend Removal Date”), deliver or
cause to be delivered to such Purchaser a certificate representing such shares that is free from all restrictive and other legends.
The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on
transfer set forth in this Section 4.8. Certificates for Securities subject to legend removal hereunder shall be transmitted by
the Transfer Agent to the Purchaser by crediting the account of the Purchaser’s prime broker with the Depository Trust Company
System as directed by such Purchaser.

 

    	24

    	 

    

 

4.9           Limitations
on Disposition. No Investor shall sell, transfer, assign or dispose of any Securities, unless:

 

(a)          there
is then in effect an effective registration statement under the Securities Act covering such proposed disposition and such disposition
is made in accordance with such registration statement; or

 

(b)          such
Investor has notified the Company in writing of any such disposition, and furnished the Company with an opinion of counsel, reasonably
satisfactory to the Company, that such disposition will not require registration of such Securities under the Securities Act; provided,
however, that no such opinion of counsel will be required (A) if the sale, transfer or assignment complies with federal and
state securities laws and is made to a fund or other institutional investor that is an Affiliate of such Investor and which is
also an “accredited investor” as that term is defined in Rule 501 of Regulation D; provided, that such Affiliate
provides the Company with customary accredited investor and investment representations (comparable with those set forth in Section
2.2 hereof), and agrees to be bound by the terms and conditions of this Agreement, (B) if the sale, transfer or assignment is made
pursuant to Rule 144 and such Investor provides the Company with evidence reasonably satisfactory to the Company that the proposed
transaction satisfies the requirements of Rule 144 or (C) in connection with a bona fide pledge or hypothecation of any
Securities under a margin arrangement with a broker-dealer or other financial institution or the sale of any such Securities by
such broker-dealer or other financial institution following such Investor’s default under such margin arrangement.

 

4.10         Disclosure
of Non-public Information. The Company agrees that it will not at any time following the Execution Date disclose material non-public
information to any Investor without first obtaining such Investor’s written consent to such disclosure, except to the extent
required by any Transaction Documents. For the avoidance of doubt, any information provided to the Battery Member in its capacity
as a member of the Board of Directors shall not be deemed a disclosure of information pursuant to this Section.

 

4.11         Listing.
Provided the Company is eligible for trading or listing, as the case may be, the Company (i) has, or promptly following the Closing
shall, use its best efforts to include
all of the Warrant Shares issuable upon exercise of the Warrants (without regard to any limitation on such exercise) for trading
on the OTCBB, and (ii) shall use its best efforts to attain designation and quotation, or listing, of the Common Stock and Warrant
Shares on the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange for
a minimum of five (5) years following the Closing Date or, in the event the Company is unable to attain such designation and quotation
or listing on the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange,
to maintain the trading of the Common Stock on the OTCBB or any successor inter-dealer trading system for a minimum of five (5)
years following the Closing Date.

 

    	25

    	 

    

 

4.12         Indemnification
of Investors. The Company will indemnify and hold each Investor and its directors, managers, officers, shareholders, members,
partners, employees and agents (each, an “Investor Party”) harmless from any and all losses, liabilities, obligations,
claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable
attorneys’ fees and costs of investigation that any such Investor Party may suffer or incur as a result of or relating to
(a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the
other Transaction Documents or (b) any action instituted against an Investor, or any of them or their respective Affiliates, by
any stockholder of the Company who is not an Affiliate of such Investor, with respect to any of the transactions contemplated by
the Transaction Documents (unless such action is based upon a breach of such Investor’s representations, warranties or covenants
under the Transaction Documents or any agreements or understandings such Investor may have with any such stockholder or any violations
by such Investor of state or federal securities laws or any conduct by such Investor which constitutes fraud, gross negligence,
willful misconduct or malfeasance). If any action shall be brought against any Investor Party in respect of which indemnity may
be sought pursuant to this Agreement, such Investor Party shall promptly notify the Company in writing, and the Company shall have
the right to assume the defense thereof with counsel of its own choosing. Any Investor Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
of such Investor Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in
writing, (ii) the Company has failed after a reasonable period of time following such Investor Party’s written request that
it do so, to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of such separate
counsel, a material conflict on any material issue between the position of the Company and the position of such Investor Party.
The Company will not be liable to any Investor Party under this Agreement (i) for any settlement by an Investor Party effected
without the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (ii) to the extent,
but only to the extent that a loss, claim, damage or liability is attributable to such Investor Party’s wrongful actions
or omissions, or gross negligence or to such Investor Party’s breach of any of the representations, warranties, covenants
or agreements made by such Investor in this Agreement or in the other Transaction Documents.

 

4.13
Indemnification of the Company. Each Investor, severally and not jointly and only to the extent of such Investor’s
Purchase Price, will indemnify and hold the Company and its directors, manager, officers, shareholders, employees and agents (each,
a “Company Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs
and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Company
Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or
agreements made by or on behalf of such Investor in this Agreement or in the other Transaction Documents or (b) any violations
by such Investor of state or federal securities laws or any conduct by such Investor which constitutes fraud, gross negligence,
willful misconduct or malfeasance. If any action shall be brought against any Company Party in respect of which indemnity may be
sought pursuant to this Agreement, such Company Party shall promptly notify the Investor in writing, and the Investor shall have
the right to assume the defense thereof with counsel of its own choosing. Any Company Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
of such Company Party except to the extent that (i) the employment thereof has been specifically authorized by such Investor in
writing, (ii) the Investor has failed after a reasonable period of time following such Company Party’s written request that
it do so, to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of such separate
counsel, a material conflict on any material issue between the position of such Investor and the position of such Company Party.
Such Investor will not be liable to any Company Party under this Agreement for any settlement by a Company Party effected without
such Investor’s prior written consent, which shall not be unreasonably withheld or delayed.

 

    	26

    	 

    

 

5.          Intentionally
Omitted.

 

6.          Conditions
to Closing.

 

6.1          Conditions
to Investors’ Obligations at the Closing. Each Investor’s obligations to effect the Closing, including without
limitation its obligation to purchase Shares and Warrants at the Closing, are conditioned upon the fulfillment (or waiver by such
Investor in its sole and absolute discretion) of each of the following events as of the Closing Date, and the Company shall use
commercially reasonable efforts to cause each of such conditions to be satisfied:

 

(a)          the
representations and warranties of the Company set forth in this Agreement and in the other Transaction Documents shall be true
and correct in all material respects as of such date as if made on such date (except that to the extent that any such representation
or warranty relates to a particular date, such representation or warranty shall be true and correct in all material respects as
of that particular date);

 

(b)          prior
to the Closing Date the Company shall have filed the Amended Charter with the Secretary of State of Delaware authorizing a number
shares of Common Stock sufficient to issue the Securities, which Amended Charter shall continue to be in full force and effect
as of the Closing Date and shall be in a form acceptable to Battery;

 

(c)          the
Company shall have complied with or performed in all material respects all of the agreements, obligations and conditions set forth
in this Agreement that are required to be complied with or performed by the Company on or before the Closing;

 

(d)          the
Company shall have delivered to such Investor a certificate, signed by the Chief Executive Officer and Chief Financial Officer
of the Company, certifying that the conditions specified in Section 6.1(a), 6.1(c), 6.1(k), 6.1(1), 6.1(m) and 6.1(n) have been
fulfilled as of
the Closing, it being understood that such Investor may rely on such certificate as though it were a representation and warranty
of the Company made herein;

 

(e)          the
Company shall have delivered to such Investor an opinion of counsel for the Company, dated as of the Closing Date, in form and
substance satisfactory to such Investor;

 

    	27

    	 

    

 

(f)          the
Company shall have delivered to such Investor duly executed certificates representing the Shares and the Warrants being purchased
by such Investor, as applicable;

 

(g)          the
Company shall have executed and delivered to the Investor the Registration Rights Agreement;

 

(h)          the
Company shall deliver to each Investor who requests it, a management rights letter which shall be in a form acceptable to Battery.

 

(i)          the
Company shall have delivered to such Investor a certificate, signed by the Secretary or an Assistant Secretary of the Company,
attaching (i) the charter and By-Laws of the Company, and (ii) resolutions passed by its Board of Directors to authorize the transactions
contemplated hereby and by the other Transaction Documents, and certifying that such documents are true and complete copies of
the originals and that such resolutions have not been amended or superseded, it being understood that such Investor may rely on
such certificate as a representation and warranty of the Company made herein;

 

(j)          the
Company shall have obtained the written agreement of each Specified Employee and critical consultant of the Company to refrain
from selling shares of Common Stock for the period specified in, and in accordance with, Section 4.1(k) hereof;

 

(k)          there
shall have occurred no material adverse change in the Company’s consolidated business or financial condition since the date
of the Company’s most recent financial statements contained in the Disclosure Documents;

 

(1)         the
Common Stock shall be traded on the OTCBB or listed on the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select
Market or the New York Stock Exchange;

 

(m)          the
Company shall have authorized and reserved for issuance the aggregate number of shares of Common Stock issuable upon exercise of
all of the Warrants to be issued at the Closing (such number to be determined without regard to any restriction on such exercise);

 

(o)          there
shall be no injunction, restraining order or decree of any nature of any court or Government Authority of competent jurisdiction
that is in effect that restrains or prohibits the consummation of the transactions contemplated hereby and by the other Transaction
Documents;

 

(p)          the Company shall have waived any applicable anti-takeover measures under Delaware
law or the Company’s charter documents that may be triggered by the actions set forth in the Transaction Documents;

 

(q)          the
Company and the Investors shall have made filings, if any, required by the Hart-Scott-Rodino Anti-Trust Improvements Act, as amended;
and

 

    	28

    	 

    

 

(r)          the
Company shall have executed an indemnification agreement with the Battery Member, in a form satisfactory to Battery, and shall
include the Battery Member on the Company’s D&O Insurance Policy.

 

6.2          Conditions
to Company’s Obligations at the Closing. The Company’s obligations to effect the Closing with each Investor are
conditioned upon the fulfillment (or waiver by the Company in its sole and absolute discretion) of each of the following events
as of the Closing Date:

 

(a)          the
representations and warranties of such Investor set forth in this Agreement and in the other Transaction Documents shall be true
and correct in all material respects as of such date as if made on such date (except that to the extent that any such representation
or warranty relates to a particular date, such representation or warranty shall be true and correct in all material respects as
of that date);

 

(b)          such
Investor shall have complied with or performed all of the agreements, obligations and conditions set forth in this Agreement that
are required to be complied with or performed by such Investor on or before the Closing;

 

(c)          there
shall be no injunction, restraining order or decree of any nature of any court or Government Authority of competent jurisdiction
that is in effect that restrains or prohibits the consummation of the transactions contemplated hereby and by the other Transaction
Documents;

 

(d)          such
Investor shall have executed each Transaction Document to which it is a party and shall have delivered the same to the Company;
and

 

(e)          such
Investor shall have tendered to the Company the Purchase Price for the Shares and the Warrant being purchased by it at the Closing
by wire transfer of immediately available funds.

 

7.           Miscellaneous.

 

7.1           Survival;
Severability. The representations, warranties, covenants and indemnities made by the parties herein and in the other Transaction
Documents shall survive the Closing notwithstanding any due diligence investigation made by or on behalf of the party seeking to
rely thereon. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to
be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided that
in such case the parties shall negotiate in good faith to replace such provision with a new provision which is not illegal, unenforceable or void, as long as such new provision does not materially change
the economic benefits of this Agreement to the parties.

 

7.2           Successors
and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors
and permitted assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other
than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations or liabilities under
or by reason of this Agreement, except as expressly provided in this Agreement. After the Closing, the Investors may assign their
respective rights and obligations hereunder, in connection with any private sale or transfer of the Shares or Warrants in accordance
with the terms hereof, as long as, as a condition precedent to such transfer, the transferee executes an acknowledgment agreeing
to be bound by the applicable provisions of this Agreement, in which case the term “Investor” shall be deemed to refer
to such transferee as though such transferee were an original signatory hereto. The Company may not assign its rights or obligations
under this Agreement.

 

    	29

    	 

    

 

7.3           No
Reliance. Each party acknowledges that (i) it has such knowledge in business and financial matters as to be fully capable of
evaluating this Agreement, the other Transaction Documents, and the transactions contemplated hereby and thereby, (ii) it is not
relying on any advice or representation or warranty of any other party in connection with entering into this Agreement, the other
Transaction Documents, or such transactions (other than the representations and warranties made in this Agreement or the other
Transaction Documents), (iii) it has not received from any party any assurance or guarantee as to the merits (whether legal, regulatory,
tax, financial or otherwise) of entering into this Agreement or the other Transaction Documents or the performance of its obligations
hereunder and thereunder, and (iv) it has consulted with its own legal, regulatory, tax, business, investment, financial and accounting
advisors to the extent that it has deemed necessary, and has entered into this Agreement and the other Transaction Documents based
on its own independent judgment and on the advice of its advisors as it has deemed necessary, and not on any view (whether written
or oral) expressed by any party.

 

7.4           Independent
Nature of Investors’ Obligations and Rights. The obligations of each Investor hereunder are several and not joint with
the obligations of the other Investors hereunder, and no Investor shall be responsible in any way for the performance of the obligations
of any other Investor hereunder. The Company acknowledges and agrees that nothing contained herein or in any other agreement or
document delivered at Closing, and no action taken by any Investor pursuant hereto or thereto, shall be deemed to constitute the
Investors as a partnership, an association, a joint venture or any other kind of entity, or a “group” as described
in Section 13(d) of the Exchange Act, or create a presumption that the Investors are in any way acting in concert with respect
to such obligations or the transactions contemplated by this Agreement. Each Investor has been represented by its own separate
counsel in connection with the transactions contemplated hereby, shall be entitled to protect and enforce its rights, including
without limitation rights arising out of this Agreement or the other Transaction Documents, individually, and shall not be required
to be join any other Investor as an additional party in any proceeding for such purpose.

 

7.5           Injunctive
Relief. The parties hereto acknowledge and agree that a breach by either of their obligations hereunder will cause irreparable
harm the other party and that the remedy or remedies at law for any such breach will be inadequate and agrees, in the event of
any such breach, in addition to all other available remedies, the non-breaching party shall be entitled to an injunction restraining
any breach and requiring immediate and specific performance of such obligations.

 

    	30

    	 

    

 

7.6           Investors’
Trading Activity. The Company acknowledges that, following the filing of the Current Report on Form 8-K described in paragraph
4.1 above, each Investor shall have the right to purchase or sell, long or short, Common Stock and instruments or contracts whose
value is derived from the market value of the Common Stock, and that sales of or certain derivative transactions relating to the
Common Stock may have a negative impact on the market price of the Common Stock.

 

7.7           Governing
Law; Jurisdiction. This Agreement shall be governed by and construed under the laws of the State of New York applicable to
contracts made and to be performed entirely within the State of New York. Each party hereby irrevocably submits to the non-exclusive
jurisdiction of the state and federal courts sitting in the City and County of New York for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby and hereby irrevocably waives, and agrees not to assert in
any such suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any manner permitted by law. In any action, suit or proceeding in any
jurisdiction brought by any party against any other party, the parties each knowingly and intentionally, to the greatest extent
permitted by applicable law, hereby absolutely, unconditionally, irrevocably and expressly waives forever trial by jury.

 

7.8           Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together
shall constitute one and the same instrument. This Agreement may be executed and delivered by facsimile transmission.

 

7.9           Headings.
The headings used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this
Agreement.

 

7.10        Notices.
Any notice, demand or request required or permitted to be given by the Company or the Investor pursuant to the terms of this Agreement
shall be in writing and shall be deemed delivered (i) when delivered personally or by verifiable facsimile transmission, unless
such delivery is made on a day that is not a Business Day, in which case such delivery will be deemed to be made on the next succeeding
Business Day, (ii) on the next Business Day after timely delivery to an overnight courier and (iii) on the Business Day actually
received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid), addressed as
follows:

 

		If to the Company:	Joel Ackerman, Chief Executive Officer

Champions Oncology, Inc.

855 North Wolfe Street,
Suite 619

Baltimore, Maryland 21205

Tel (410) 369-0365

Fax (410) 369-0390

jackerman@championsoncology.com

 

    	31

    	 

    

 

		with a copy to:	Hillel Tendler, Esquire

Neuberger, Quinn, Gielen, Rubin &
Gibber, P.A.

One South Street, 27th
Floor

Baltimore, Maryland 21202

Tel (41) 332-8552

Fax (410) 332-8553

ht@nqgrg.com

 

and if to any Investor, to such address for
such Investor as shall appear on the signature page hereof executed by such Investor, or as shall be designated by such Investor
in writing to the Company in accordance with this Section 7.10.

 

7.11  Expenses. The
Company and each Investor shall pay all costs and expenses that it incurs in connection with the negotiation, execution, delivery
and performance of this Agreement or the other Transaction Documents, provided, however, that that the Company shall, at
the Closing, pay up to $75,000 in immediately available funds for all reasonable, documented out-of-pocket expenses (including
without limitation reasonable legal fees and expenses) incurred or to be incurred by Battery in connection its due diligence investigation
of the Company and the negotiation, preparation, execution, delivery and performance of this Agreement and the other Transaction
Documents.

 

7.12 Entire Agreement;
Amendments.  This Agreement and the other Transaction Documents constitute the entire agreement between the parties with regard
to the subject matter hereof and thereof, superseding all prior agreements or understandings, whether written or oral, between
or among the parties. Except as expressly provided herein, neither this Agreement nor any term hereof may be amended except pursuant
to a written instrument executed by the Company and the holders of at least a majority of the Shares and Warrant Shares into which
all of the Warrants then outstanding are exercisable (without regard to any limitation on such exercise), and no provision hereof
may be waived other than by a written instrument signed by the party against whom enforcement of any such waiver is sought. Any
waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

[Signature Pages to Follow]

 

    	32

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have
executed this Agreement as of the date first written above.

 

	 	CHAMPIONS ONCOLOGY, INC.
	 	 	 
	 	By:	/s/ Joel Ackerman
	 	 	Name:	Joel Ackerman
	 	 	Title:	Chief Executive Officer

 

	 	BATTERY VENTURES IX, L.P.
	 	By:	Battery Partners IX, LLC
	 	 	General Partner
	 	 	 	 	 
	 	 	By:	/s/ Scott Tobin
	 	 	 	Name:	Scott Tobin
	 	 	 	Title:	Member Manager

 

	 	BATTERY INVESTMENT PARTNERS, IX, LLC
	 	By:	Battery Partners IX, LLC
	 	 	Managing Member
	 	 	 	 	 
	 	 	By:	/s/ Scott Tobin
	 	 	 	Name:	Scott Tobin
	 	 	 	Title:	Member Manager

 

	 	/s/ Joel Ackerman
	 	Joel Ackerman
	 	 
	 	/s/ Ronnie Morris
	 	Ronnie Morris

 

    	33

    	 

    

 

SCHEDULE OF INVESTORS 

 

	Name	 	Purchase 
 Price	 	 	Number of 
 Shares	 	 	Number of 
 Warrants	 
	Battery Ventures IX, L.P.	 	$	4,059,410	 	 	 	5,412,547	 	 	 	811,882	 
	Battery Investment Partners IX, LLC	 	$	40,590	 	 	 	54,120	 	 	 	8,118	 
	Harris & Harris Group, Inc.	 	$	2,000,000	 	 	 	2,666,667	 	 	 	0	 
	Perceptive Life Sciences Master Fund Ltd.	 	$	1,250,000	 	 	 	1,666,667	 	 	 	0	 
	Porter Partners, L.P.	 	$	340,000	 	 	 	453,333	 	 	 	0	 
	EDJ Limited	 	$	60,000	 	 	 	80,000	 	 	 	0	 
	Northwood Capital Partners LP	 	$	200,000	 	 	 	266,667	 	 	 	0	 
	The Oliver D. Curme Children’s Trust - 1997	 	$	500,000	 	 	 	666,667	 	 	 	100,000	 
	Richard L. Sandor Revocable Trust	 	$	250,000	 	 	 	333,333	 	 	 	50,000	 
	Ronnie Morris, M.D.	 	$	250,000	 	 	 	333,333	 	 	 	0	 
	Joel Ackerman	 	$	250,000	 	 	 	333,333	 	 	 	0	 
	Steve Geller	 	$	100,000	 	 	 	133,333	 	 	 	20,000	 
	Bernard Kaminetsky 	 	$	100,000	 	 	 	133,333	 	 	 	20,000	 
	TOTAL	 	$	9,400,000	 	 	 	12,533,333	 	 	 	1,010,000	 

 

    	34

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]